CARTRIDGE FOR NUCLEIC ACID AMPLIFICATION REACION

BACKGROUND

1. Technical Field

The present invention relates to a cartridge for nucleic acid amplification reaction.

2. Related Art

Boom et al. reported a method which makes it easier to extract the nucleic acid from biomaterials by using nucleic acid-binding solid-phase carriers such as silica particles and a chaotropic agent (see J. Clin. Microbiol., vol. 28, No. 3, pp 495-503 (1990)). The methods, which include the method reported by Boom et al., of causing the nucleic acid to be adsorbed onto carriers by using nucleic acid-binding solid-phase carriers such as silica and a chaotropic agent and extracting the nucleic acid mainly include three steps including (1) a step of causing nucleic acid to be adsorbed onto nucleic acid-binding solid-phase carriers in the presence of a chaotropic agent (adsorption step), (2) a step of washing the carriers having been adsorbed onto the nucleic acid with a washing solution so as to remove foreign substances, which have bound to the carriers in a nonspecific manner, and the chaotropic agent (washing step), and (3) a step of causing elution of the nucleic acid by using water or a low salt-concentration buffer solution (elution step).

Incidentally, in recent years, in addition to the PCR devices of the related art, thermal cycling devices which make it easy to control heating time have been developed (see JP-A-2012-115208). However, a cartridge suitable for these devices has not yet been developed.

SUMMARY

An advantage of some aspects of the invention is that it provides a cartridge for nucleic acid amplification reaction that can make it easy to perform a nucleic acid amplification reaction.

A cartridge for nucleic acid amplification reaction according to an aspect of the invention includes a tube that has a first plug formed of a first oil, a second plug formed of a second washing solution which undergoes phase separation when being mixed with oil and washes nucleic acid-binding solid-phase carriers having bound to nucleic acid, a third plug formed of a second oil, a fourth plug formed of a reverse transcription reaction solution which undergoes phase separation when being mixed with oil and in which a reverse transcription reaction occurs, a fifth plug formed of a third oil, a sixth plug formed of an eluate which undergoes phase separation when being mixed with oil and causes the nucleic acid to be eluted from the nucleic acid-binding solid-phase carriers having bound to the nucleic acid, and a seventh plug formed of a fourth oil in this order in the inside of the tube; a container for nucleic acid amplification reaction that is in communication with the side of the seventh plug of the tube and contains oil; and a plunger that is mounted on an opening portion of the side of the first plug of the tube and pushes liquid to the container for nucleic acid amplification reaction out of the side of the seventh plug of the tube. In the cartridge, the tube may further have a tenth plug formed of a third washing solution that undergoes phase separation when being mixed with oil and washes the nucleic acid-binding solid-phase carriers having bound to the nucleic acid and an eleventh plug formed of a sixth oil in this order from the side of the fifth plug, between the fifth plug and the sixth plug. The tube may further have an eighth plug formed of a nucleic acid amplification reaction solution that undergoes phase separation when being mixed with oil and contains a reagent for causing a nucleic acid amplification reaction and a ninth plug formed of a fifth oil in this order from the side of the seventh plug, at the side of the seventh plug close to the container for nucleic acid amplification reaction. The container for nucleic acid amplification reaction may contain a droplet of a nucleic acid amplification reaction solution that undergoes phase separation when being mixed with oil and contains a reagent for causing a nucleic acid amplification reaction. The reagent for causing a nucleic acid amplification reaction may be contained in the eluate. It is preferable for the reagent for causing a nucleic acid amplification reaction to contain a DNA polymerase, dNTP, and primers.

The plunger of one of the above cartridges may accommodate oil and a first washing solution which undergoes phase separation when being mixed with oil and washes the nucleic acid-binding solid-phase carriers having bound to the nucleic acid in the inside thereof. Moreover, the container for nucleic acid amplification reaction may have a seal formation portion to which the tube is fixed, and a flow path formation portion through which the solution droplet moves. It is preferable for the seal formation portion to have an oil accommodating portion that accommodates oil overflowing from the flow path formation portion.

One of the above cartridges may further have a tank that is in communication with the side of the first plug of the tube and introduces the nucleic acid-binding solid-phase carriers into the tube. It is preferable for the tank and the tube to be bonded to each other through the plunger.

A kit of a cartridge for nucleic acid amplification reaction according to another aspect of the invention includes one of the above cartridges for nucleic acid amplification reaction and a tank that introduces the nucleic acid-binding solid-phase carriers to the tube. The tank may contain a lysing solution that causes elution of the nucleic acid and the nucleic acid-binding solid-phase carriers. The tank may have an opening portion, and the opening portion may have a detachable lid. The opening portion of the tank may be constituted such that this opening portion can be mounted on an opening portion of the tube that is at the side of the first plug.

The aspects of the invention can provide a cartridge for nucleic acid amplification reaction that can make it easy to perform a nucleic acid amplification reaction.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be described with reference to the accompanying drawings, wherein like numbers reference like elements.

FIGS. 1A to 1C are views for illustrating a cartridge according to an embodiment of the invention.

FIGS. 2A to 2C are views for illustrating the operation of the cartridge according to an embodiment of the invention.

FIGS. 3A to 3D are views for illustrating a tank according to an embodiment of the invention.

FIG. 4 is a view for illustrating a fixing claw, a guide plate, and a mounting portion according to an embodiment of the invention.

FIGS. 5A and 5B are views for illustrating the periphery of a PCR container according to an embodiment of the invention.

FIG. 6A is a perspective view of the internal constitution of a PCR device according to an embodiment of the invention. FIG. 6B is a lateral view of the main constitution of the PCR device according to an embodiment of the invention.

FIG. 7 is a block diagram of the PCR device according to an embodiment of the invention.

FIG. 8A is a view for illustrating a rotary body according to an embodiment of the invention. FIG. 8B is a view for illustrating a state where the cartridge has been mounted on the mounting portion of the rotary body according to an embodiment of the invention.

FIGS. 9A to 9D are views for illustrating a state of the PCR device at the time when the cartridge is mounted on the device according to an embodiment of the invention.

FIG. 10 is a schematic view showing the behavior of magnetic beads at the time when magnets are moved downward according to an embodiment of the invention.

FIGS. 11A to 11C are views for illustrating nucleic acid elution process according to an embodiment of the invention.

FIG. 12 is a schematic view showing the behavior of the magnetic beads at the time when the magnets are caused to oscillate according to an embodiment of the invention.

FIG. 13 is a table showing whether or not the magnets oscillate in an embodiment of the invention.

FIGS. 14A to 14C are views for illustrating solution droplet formation process according to an embodiment of the invention.

FIGS. 15A to 15D are views for illustrating thermal cycling process according to an embodiment of the invention.

FIGS. 16A and 16B are schematic views showing the constitution of a nucleic acid extraction instrument according to an example of the invention.

FIG. 17 is a schematic view showing the constitution of a nucleic acid extraction device according to an example of the invention.

FIG. 18 is a view showing how to use rectangular magnets in a nucleic acid extraction method according to an example of the invention.

FIGS. 19A and 19B are views in which a capillary (1-step) for 1-step elution and a capillary (2-step) for 2-step elution according to an example of the invention are compared to each other in terms of the temporal change of detection sensitivity that is exhibited when PCR is performed using nucleic acid-containing eluate obtained from each of the capillaries.

FIG. 20 is a view in which a capillary (1-step) for 1-step elution and a capillary (2-step) for 2-step elution according to an example of the invention are compared to each other in terms of detection sensitivity that is exhibited when PCR is performed using a nucleic acid-containing eluate obtained from each of the capillaries.

FIG. 21 is a view in which capillaries (2-step) for 2-step elution according to an example of the invention are compared to each other for a case where the capillary further contains a plug formed of a washing solution after a reverse transcription reaction plug and a case where the capillary does not contain a plug formed of a washing solution after a reverse transcription reaction plug, in terms of detection sensitivity that is exhibited when PCR is performed using a nucleic acid-containing eluate obtained from each of the capillaries.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

Hereinafter, embodiments of the invention will be described in detail. The description of the present specification makes those skilled in the art clearly see the object, characteristics, advantages, and ideas of the invention, and those skilled in the art can easily make the invention based on the description of the present specification. The embodiments of the invention described below are preferable embodiments of the invention, and the invention is not limited thereto. Those skilled in the art know for sure that the invention can be changed and modified in various ways based on the description of the present specification within the intention and the scope of the invention described in the specification.

First, the cartridge to be mounted on the PCR device 100 will be described, and then the constitution and operation of the PCR device 100 of the present embodiment will be described.

Cartridge

FIGS. 1A to 1C are views for illustrating the cartridge 1. FIGS. 2A to 2C are views for illustrating the operation of the cartridge 1. FIG. 2A is a view for illustrating the initial state of the cartridge 1. FIG. 2B is a lateral view showing a state where a plunger 10 is pushed in the state described in FIG. 2A such that a seal 12A comes into contact with a lower syringe 22. FIG. 2C is a view for illustrating the cartridge 1 in which the plunger 10 has been pushed.

The cartridge 1 is a container in which nucleic acid elution process for causing a nucleic acid to be eluted into an eluate 49 from magnetic beads 7 having bound to the nucleic acid is conducted. The cartridge 1 is also a container in which thermal cycling process of a polymerase reaction is performed on a mixed solution (hereinafter, referred to as a “PCR solution”) containing a nucleic acid to be amplified and a reagent for causing a nucleic acid amplification.

The nucleic acid extraction process is performed in a tank 3, and the nucleic acid is purified while passing through a tube 20. The material of the tube 20 is not particularly limited, and the tube can be made of, for example, glass, resins such as plastic, and metals. Particularly, it is preferable to select transparent glass or resin as the material of the tube 20, since the cavity of the tube 20 can be observed from the outside. Moreover, it is preferable to select materials that transmits magnetic force or nonmagnetic materials as the material of the tube 20, since this makes it easy to apply magnetic force from the outside of the tube 20 when magnetic particles are passed through the tube 20. In addition, the tube 20 and the tank may be made of the same material.

The tube 20 has a second washing solution plug 45, a reverse transcription reaction solution plug 47, an eluate plug 49, and oil plugs. Since the magnetic beads 7 having bound to the nucleic acid are attracted to a magnet of the outside, if the magnet is moved at the outside along the tube 20, the magnetic beads 7 move inside the tube 20, pass through the second washing solution plug 45 and the reverse transcription reaction solution plug 47, and reach the eluate plug 49. The nucleic acid having bound to the magnetic beads 7 is washed with the washing solution in the second washing solution plug 45, undergoes reverse transcription in the reverse transcription reaction solution plug 47, and is eluted in the eluate plug 49. The “plug” refers to a certain liquid that takes up a section inside the tube 20. For example, in FIGS. 2A to 2C, the liquid held in the form of a column inside a capillary 23 is called a “plug”. Oil undergoes phase separation from other liquids. Therefore, a plug formed of the oil functions to prevent the plugs at both sides of the plug from being mixed with each other. It is preferable for air bubbles or other liquids not to be present in a plug or between plugs. However, as long as the magnetic beads 7 can pass through the plug, air bubbles or other liquids may be present.

The type of oil is not particularly limited, and mineral oil, silicone oil (such as 2CS silicone oil), plant oil, and the like can be used. However, if oil having a higher viscosity is used, when the nucleic acid-binding solid-phase carriers are moved in the interface between the oil and the upper plug, a “wiping effect” produced by the oil can be enhanced. Consequently, when the nucleic acid-binding solid-phase carriers are moved from the upper plug to the plug formed of the oil, it is possible to make it more difficult for water-soluble components, which have adhered to the nucleic acid-binding solid-phase carriers, to be mixed into the oil.

The thermal cycling process is performed in the PCR container 30 of the cartridge 1. The PCR container 30 is filled with oil, and a PCR solution 40 undergoes phase separation when being mixed with oil the oil. Therefore, when being pushed out of the tube 20 to the oil, the eluate plug 49 and the like become the PCR solution 40 in the form of a droplet. The PCR solution 40 in the form of a droplet is precipitated since the specific gravity thereof is greater than that of the oil. When a high-temperature region 36A and a low-temperature region 36B are formed in the PCR container 30 by external heaters, and the entire cartridge 1 is repeatedly moved upside down together with the heaters, the PCR solution 40 alternately moves between the high-temperature region 36A and the low-temperature region 36B, whereby two-step temperature process is performed on the PCR solution 40.

The material of the PCR container 30 is not particularly limited, and the PCR container 30 can be formed of, for example, glass, resins such as plastic, and metals. Furthermore, it is preferable for the material of the PCR container 30 to be heat resistant to a temperature of at least 100° C. or higher since the high temperature-side heater 65B is disposed near the container. It is preferable to select transparent or semitransparent materials as the material of the PCR container 30, since this makes it easy to perform fluorescence assay (luminance measurement). However, the entire region of the PCR container 30 does not need to be transparent or semitransparent, and at least the site (for example, a bottom 35A of the PCR container 30) facing a fluorescence measuring instrument 55 may be transparent or semitransparent. In addition, the tube 20 and the tank 3 or the plunger 10 may be made of the same material.

The cartridge 1 is constituted with the tank 3 and a cartridge main body 9. In a kit constituting the cartridge 1, the tank 3, and cartridge main body 9, and an adapter 5 are prepared in advance. The tank 3 and the cartridge main body 9 are connected to each other through the adapter 5, whereby the cartridge 1 is assembled. However, the cartridge 1 can also be constituted by directly connecting the tank 3 to the cartridge main body 9.

In the following description of the constituents of the cartridge 1, as described in FIG. 2A, the direction extending along the long cartridge 1 is described as a “longitudinal direction”, the side of the tank 3 is described as an “upstream side”, and the side of the PCR container 30 is described as a “downstream side”. Moreover, in some cases, the upstream side and the downstream side are simply described as “upper side” and “lower side” respectively.

(1) Tank

FIGS. 3A to 3D are views for illustrating the tank 3.

The tank 3 prepared in advance in the kit contains a lysing solution 41 and magnetic beads 7. The opening of the tank 3 is provided with a detachable lid 3A (see FIG. 3A). As the lysing solution 41, 5 M of guanidine thiocyanate, 2% Triton X-100, and 50 mM of Tris-HCl (pH 7.2) are used. An operator removes the lid 3A to open the opening of the tank 3 (see FIG. 3B), and dips a cotton swab smeared with a virus into the lysing solution 41 in the tank 3 to collect the virus in the lysing solution 41 (see FIG. 3C). When the liquid in the tank 3 is stirred, the tank 3 may be shaken in the state described in FIG. 3C. However, in doing so, the lysing solution 41 easily overflows. Accordingly, it is preferable to shake the tank 3 after the adapter 5 covered with a lid 5A is mounted on the opening of the tank 3 as shown in FIG. 3D. In this manner, the substance in the tank 3 is stirred, the virus particles undergo lysis by the lysing solution 41, whereby the nucleic acid is liberated, and silica that has coated the magnetic beads 7 absorbs the nucleic acid. Thereafter, the operator detaches the lid 5A of the adapter 5 mounted on the opening of the tank 3, and mounts the tank 3 on the cartridge main body 9 through the adapter 5 (see FIG. 2A).

The tank 3 is constituted with a flexible resin and is dilatable. When the state of the cartridge changes as shown in FIG. 2B from the state shown in FIG. 2A due to sliding of the plunger 10, the tank 3 dilates, and this prevents the pressure of the liquid in the tube 20 from excessively increasing and the liquid in the tube 20 from being pushed out to the downstream side. It is desirable to form a deformation portion 3B in the tank 3 such that the tank 3 easily dilates.

The sample used for the extraction and amplification of the nucleic acid is not limited to viruses and may be cells. The sources of cells are not particularly limited and may be microorganisms, tissue fragments or blood of higher organisms, and the like.

The lysing solution is not particularly limited as long as it contains a chaotropic substance, and may contain a surfactant to destruct the cell membrane or denature proteins contained in the cells. The surfactant is not particularly limited as long as it is generally used for extracting the nucleic acid from cells and the like. Specific examples thereof include nonionic surfactants including triton-based surfactants such as Triton-X or tween-based surfactants such as Tween-20, and anionic surfactants such as N-lauroylsarcosine sodium (SDS). However, it is particularly preferable to use nonionic surfactants at a concentration within a range of 0.1% to 2%. Moreover, it is preferable for the lysing solution to contain a reductant such as 2-mercaptoethanol or dithiothreitol. The lysing solution may be a buffer solution, and pH thereof is preferably neutral such as pH 6 to 8. Considering the above, specifically, it is preferable for the lysing solution to contain 3 M to 7 M of a guanidine salt, 0% to 5% of a nonionic surfactant, 0 mM to 0.2 Mm of EDTA, 0 M to 0.2 M of a reductant, and the like.

The chaotropic substance acts to generate chaotropic ions (monovalent anions having a large diameter) in an aqueous solution and enhance water solubility of hydrophobic molecules. This substance is not particularly limited as long as it contributes to the adsorption of the nucleic acid onto the solid-phase carriers. Specific examples thereof include guanidine thiocynate, guanidine hydrochloride, sodium iodide, potassium iodide, sodium perchlorate, and the like. Among these, guanidine thiocynate or guanidine hydrochloride having a potent protein denaturating action is preferable. The concentration of these chaotropic substances used varies with the type of each of the substances. For example, when guanidine thiocyanate is used, this substance is preferably used in a range of 3 M to 5.5 M, and when guanidine hydrochloride is used, this substance is preferably used at a concentration of 5 M or more.

The tool for collecting the sample is not particularly limited, and instead of a cotton swab, a spatula, a rod, a scraper, and the like may be selected according to the purpose.

The internal volume of the tank 3 is not particularly limited, and may be, for example, from 0.1 mL to 100 mL. The material of the tank 3 is not particularly limited, and the tank 3 can be made of, for example, glass, resins such as plastic, and metals. Particularly, it is preferable to select transparent glass or resins as the material of the tank, since the inside of the tank 3 can be observed from the outside. The tank 3 and each tube 20 may be formed by monolithic molding or may be detachable from each other. If flexible materials such as rubber, elastomers, and polymers are used as the material of the tank 3, it is possible to increase the internal pressure of the tank 3 by deforming the tank 3 in a state where the tank 3 is covered with a lid. As a result, it is possible to push the content of the tube 20 out of the tip of the tube toward the outside from the inside of the tube.

(2) Cartridge Main Body

The cartridge main body 9 has the plunger 10, the tube 20, and the PCR container 30.

(2-1) Plunger

Hereinafter, the plunger 10 will be described with reference to FIGS. 2A to 2C.

The plunger 10 is a movable plunger pushing out liquid from the downstream side of the tube 20 which functions as a syringe. The plunger 10 functions to push out a predetermined amount of liquid in the tube 20 to the PCR container 30 from the end of the tube 20. The plunger 10 also functions to mount the tank 3 on the cartridge through the adapter 5.

The plunger 10 has a cylindrical portion 11 and a rod-like portion 12. The cylindrical portion 11 is disposed at tank 3 side (upstream side), and the rod-like portion 12 is disposed at the tube 20 side (downstream side). The rod-like portion 12 is supported by two plate-like ribs 13 from the inner wall of the downstream side of the cylindrical portion 11. The downstream side of the rod-like portion 12 protrudes toward the downstream side from the cylindrical portion 11.

The cylindrical portion 11 is opened toward the upstream side and the downstream side, and the inner wall of the cylindrical portion 11 functions as a path of liquid. The opening of the upstream side (tank 3 side) of the cylindrical portion 11 fits to the adapter 5. In the plunger 10 of the cartridge main body 9 which is prepared in advance as a kit, a detachable lid may be mounted on the opening of the upstream side of the cylindrical portion 11. The opening of the downstream side of the cylindrical portion 11 is positioned in the inside of the upper syringe 21 of the tube 20. The magnetic beads 7 introduced from the opening of the upstream side of the cylindrical portion 11, pass through the inside of the cylindrical portion 11, escape from the inside and outside of the ribs 13, come out of the opening of the downstream side of the cylindrical portion 11, and are introduced into the upper syringe 21 of the tube 20.

The downstream side of the cylindrical portion 11 fits to the inner wall of the upper syringe 21 of the tube 20. The cylindrical portion 11 can slide relative to the upper syringe 21 in the longitudinal direction while coming into contact with the inside of the upper syringe 21 of the tube 20.

In the periphery of the opening of the upstream side of the cylindrical portion 11, a mounting board 11A for mounting the adapter 5 is formed. The mounting board 11A also functions as a portion which is pushed when the plunger 10 is pushed. When the mounting board 11A is pushed, the plunger 10 slides relative to the tube 20, whereby the state of the cartridge changes as described in FIG. 2C from the state described in FIG. 2A. When the plunger 10 moves to the downstream side, the mounting board 11A comes into contact with the upper rim of the tube 20 (see FIG. 2C). That is, the interval between the mounting board 11A of the plunger 10 and the upper rim of the tube 20 is a sliding length of the plunger 10.

In the initial state, the rod-like portion 12 is positioned in the inside of the upper syringe 21 of the tube 20 and is separated from the lower syringe 22 (see FIG. 2A). When the plunger 10 slides relative to the tube 20, the rod-like portion 12 is inserted into the lower syringe 22 of the tube 20 and slides relative to the lower syringe 22 in the downstream direction while being coming into contact with the inside of the lower syringe 22 (see FIGS. 2B and 2C).

The cross-section of the rod-like portion 12 that is perpendicular to the longitudinal direction has a circular shape. However, the cross-sectional shape of the rod-like portion 12 may be circular, oval, or polygonal and is not particularly limited, as long as the rod-like portion 12 can fit to the inner wall of the lower syringe 22 of the tube 20.

The seal 12A is formed at the edge of the downstream side of the rod-like portion 12. When the seal 12A fits into the lower syringe 22, the liquid in the tube 20 of the downstream side is prevented from flowing back toward the upper syringe 21. Moreover, while the plunger 10 is being pushed such that the state of the cartridge changes to the state described in FIG. 2C from the state described in FIG. 2B, the liquid in the tube 20 is pushed out of the downstream side, by the amount corresponding to the volume in which the seal 12A slides inside the lower syringe 22.

The material of the plunger 10 is not particularly limited, and the plunger 10 can be made of, for example, glass, resins such as plastic, and metals. Moreover, the cylindrical portion 11 and the rod-like portion 12 of the plunger 10 may be formed of the same material as a monolithic member, or may be formed of different materials. Herein, the cylindrical portion 11 and the rod-like portion 12 are separately molded with a resin, and the cylindrical portion 11 is joined with the rod-like portion 12 through the ribs 13, whereby the plunger 10 is formed.

The plunger 10 accommodates the oil 42 constituting the first plug and the first washing solution 43 constituting the second plug in advance in the inside thereof. The specific gravity of the oil 42 in the plunger 10 is smaller than that of the first washing solution 43. Accordingly, when the tank 3 is mounted on the cartridge main body 9, if the cartridge main body 9 is made to stand such that the mounting board 11A of the plunger 10 becomes the upper side, the oil 42 is disposed between the liquid in the tank 3 and the first washing solution 43 of the cartridge main body 9 as shown in FIG. 2A. The oil 42 is not particularly limited, but it is preferable to use 2CS silicone oil. The first washing solution 43 is not particularly limited. However, the first washing solution 43 may be liquid that undergoes phase separation when being mixed with any of the oil 42 constituting the first plug and the oil 44 constituting the third plug. It is preferable for the first washing solution 43 to be water or an aqueous solution with a low salt concentration, and the aqueous solution with a low salt concentration is preferably a buffer solution. The salt concentration of the aqueous solution with a low salt concentration is preferably 100 mM or less, more preferably 50 mM or less, and most preferably 10 mM or less. The lower limit of the salt concentration of the aqueous solution with a low salt concentration is not particularly limited, but is preferably 0.1 mM or higher, more preferably 0.5 mM or higher, and most preferably 1 mM or higher. This solution may also contain a surfactant such as Triton, Tween, or SDS, and pH thereof is not particularly limited. The type of salt for making the buffer solution is not particularly limited, and salts of TRIS, HEPES, PIPES, phosphoric acid, and the like are preferably used. Particularly, it is preferable to use 8 M guanidine hydrochloride and 0.7% Triton X-100. In addition, it is preferable for the first washing solution to contain alcohol in such an amount that does not hinder the adsorption of nucleic acid onto carriers, a reverse transcription reaction, a PCR reaction, and the like. In this case, the concentration of alcohol is not particularly limited and may be 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, or 10% or less. However, the concentration is preferably 5% or less or 2% or less, more preferably 1% or less or 0.5% or less, and most preferably 0.2% or less or 0.1% or less.

The first washing solution 43 may contain a chaotropic agent. For example, if the first washing solution 43 contains guanidine hydrochloride, it is possible to wash particles and the like while maintaining or reinforcing the adsorption state of the nucleic acid having been adsorbed onto the particles and the like. When the washing solution contains guanidine hydrochloride, the concentration of this agent can be controlled to be 3 mol/L to 10 mol/L and preferably from 5 mol/L to 8 mol/L. If the concentration of guanidine hydrochloride is within the above range, it is possible to wash off foreign substances and the like while further stabilizing the adsorption state of the nucleic acid having been adsorbed onto particles and the like.

(2-2) Tube

Hereinafter, the tube 20 will be described with reference to FIGS. 1A to 1C and FIGS. 2A to 2C.

The tube 20 has the shape of a cylinder through which liquid can flow in the longitudinal direction. The tube 20 has the upper syringe 21, the lower syringe 22, and a capillary 23, and the inner diameter of each of these portions varies stepwise.

The upper syringe 21 has the shape of a cylinder through which liquid can flow in the longitudinal direction. The cylindrical portion 11 of the plunger 10 slidably comes into contact with the inner wall of the upper syringe 21. The upper syringe 21 functions as a syringe for the cylindrical portion 11 of the plunger 10.

The lower syringe 22 has the shape of a cylinder through which liquid can flow in the longitudinal direction. The seal 12A of the rod-like portion 12 of the plunger 10 can slidably fit to the inner wall of the lower syringe 22. The lower syringe 22 functions as a syringe for the rod-like portion 12 of the plunger 10.

The capillary 23 has the shape of a capillary tube through which liquid can flow in the longitudinal direction. The inner diameter of the capillary 23 has such a size that enables the liquid to be maintained in the form of a plug. Herein, the inner diameter is 1.0 mm. The inner diameter of terminal (terminal of the downstream side of the tube 20) of the capillary 23 is 0.5 mm which is smaller than the aforementioned diameter. The inner diameter of terminal of the capillary 23 is set to be smaller than the diameter (1.5 mm to 2.0 mm) of the nucleic acid amplification reaction solution, which will be described later, in the form of a droplet. As a result, when a plug (for example, the eluate plug 49) containing a nucleic acid to be amplified or a plug (for example, the eluate plug 49 or a nucleic acid amplification reaction solution plug 50A) containing a reagent for causing a nucleic acid amplification reaction is pushed out of the terminal of the capillary 23, it is possible to prevent the nucleic acid amplification reaction solution (for example, the PCR solution 40) in the form of a droplet from adhering to the terminal of the capillary 23 or from flowing back into the capillary.

The capillary 23 may have a cavity in the inside thereof and have the shape of a cylinder through which liquid can flow in the longitudinal direction. The capillary 23 may be curved in the longitudinal direction, but it is preferable for the capillary 23 to be straight. The internal cavity of the tube is not particularly limited in terms of the size and shape, as long as liquid can be maintained in the form of a plug inside the tube. Moreover, the size of the internal cavity of the tube or the shape of a cross-section thereof perpendicular to the longitudinal direction may be varied along the longitudinal direction of the tube.

The shape of the cross-section of the tube that is perpendicular to the longitudinal direction of the exterior of the tube is not limited. Moreover, the thickness (a distance between the lateral wall of the internal cavity and the exterior surface) of the tube is not particularly limited. When the tube has the shape of a cylinder, the inner diameter (diameter of a circle which is a cross-section perpendicular to the longitudinal direction of the internal cavity) can be set to, for example, 0.5 mm to 2 mm. If the inner diameter of the tube is within the above range, it is easy to form a plug of liquid within a wide range of tube materials and liquid type. It is preferable for the tube to be tapered toward the tip, and the diameter of the tip can be set to 0.2 mm to 1 mm. If the inner diameter of the terminal of the capillary 23 (diameter of opening of the capillary 23) is set to be small, it is possible to inhibit the PCR solution 40, which has been made into a droplet in the PCR container 30, from being adsorbed onto the opening of the capillary 23 and becoming inseparable. However, if the inner diameter of terminal of the capillary 23 is too small, a large number of small droplets of the PCR solution 40 are formed. In addition, in the capillary 23, if the diameter of portion other than the terminal is made small just like the terminal, it is not desirable since the cartridge 1 will be lengthened to secure the volume of each plug.

In the inside of the capillary 23, the first oil plug 44, the second washing solution plug 45, the second oil plug 46, the reverse transcription reaction solution plug 47, the third oil plug 48, the eluate plug 49, and a fourth oil plug 50 are present in this order from the upstream side (FIG. 1A). That is, oil plugs are disposed at both sides of water-soluble plugs (the washing solution plugs 45/48A, the reverse transcription reaction solution plug 47, and the eluate plug 49).

In the upper syringe 21 and the lower syringe 22 at the upstream side from the first oil plug 44, the oil 42 and the first washing solution 43 have already been accommodated (see FIG. 2A). The inner diameter of the upper syringe 21 and the lower syringe 22 is larger than the inner diameter of the capillary 23. In the upper syringe 21 and the lower syringe 22, the liquid (the oil 42 and the first washing solution 43) cannot be maintained in the form of a column just like a plug. However, since the first oil plug 44 is held in the form of a plug by the capillary 23, the oil constituting the first oil plug 44 is inhibited from moving to the upstream side.

The second washing solution plug 45 may be formed of 5 mM of tris-hydrochloric acid buffer solution which is a second washing solution. The second washing solution may be constituted basically in the same manner as the first washing solution described above or may be the same as or different from the first washing solution. However, in order to prevent a chaotropic substance from being mixed into the solution after the second washing solution, it is preferable for the second washing solution to be a solution which substantially does not contain the chaotropic substance. As described above, it is preferable for this second washing solution to contain alcohol in such an amount that does not hinder the adsorption of the nucleic acid onto carriers, a reverse transcription reaction, a PCR reaction, and the like. The concentration of alcohol is not particularly limited and may be 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, or 10% or less. However, the concentration is preferably 5% or less or 2% or less, more preferably 1% or less or 0.5% or less, and most preferably 0.2% or less or 0.1% or less.

The second washing solution plug 45 may be constituted with plural plugs divided by oil plugs. When the second washing solution plug 45 consists of plural plugs, the liquids of the respective plugs may be the same as or different from one another. If at least one of the plugs is a plug of a second washing solution, the liquids of other plugs are not particularly limited. However, it is preferable for all plugs to be the second washing solutions. The number of divided plugs of the second washing solution plug 45 can be appropriately set in consideration of, for example, the length of the tube 20 or the subject to be washed.

The reverse transcription reaction solution contained in the reverse transcription reaction solution plug 47 contains a reverse transcriptase, dNTP, and a primer for a reverse transcriptase (oligonucleotide). The solvent is not particularly limited and is preferably water. It is preferable for the reverse transcription reaction solution to be a solution that substantially does not contain an organic solvent such as ethanol or isopropanol and a chaotropic substance. Moreover, it is preferable for the reverse transcription reaction solution to contain a salt such that the reaction solution becomes a buffer for a reverse transcriptase. The salt that makes the reaction solution be a buffer solution is not particularly limited as long as the salt does not hinder an enzyme reaction. However, salts of TIS, HEPES, PIPES, phosphoric acid, and the like are preferably used. The reverse transcriptase is not particularly limited, and for example, it is possible to use reverse transcriptase derived from avian myeloblast virus, ras-associated virus type 2, mouse moloney murine leukemia virus, and human immunodeficiency virus type 1. However, it is preferable to use heat-resistant enzymes. The concentration of dNTP or salt contained in the reverse transcription reaction solution may be set appropriately depending on the type of the enzyme to be used. However, generally, the concentration of dNTP is 10 μM to 1,000 μM and preferably 100 μM to 500 μM, the concentration of Mg²⁺ is preferably 1 mM to 100 mM and preferably 5 mM to 10 mM, and the concentration of Cl⁻ is 1 mM to 2,000 mM and preferably 200 mM to 700 mM. The total ion concentration is not particularly limited, but is preferably higher than 50 mM, more preferably higher than 100 mM, even more preferably higher than 120 mM, still more preferably higher than 150 mM, and yet more preferably higher than 200 mM. The upper limit thereof is preferably 500 mM or less, more preferably 300 mM or less, and even more preferably 200 mM or less. The oligonucleotides for a primer are used at a concentration of 0.1 μM to 10 μM, and preferably at a concentration of 0.1 μM to 1 μM respectively. The reaction solution may contain BSA, gelatin, or the like as a carrier. If the concentration of BSA or gelatin is 1 mg/mL or less, the reaction hindrance inhibitory effect is diminished, and if the concentration is 10 mg/mL or higher, the reverse transcription reaction and the following enzyme reaction may be hindered. Accordingly, the concentration is preferably 1 mg/mL to 10 mg/mL. When gelatin is used, the source thereof is not particularly limited, and examples thereof include cowhide, pig hide, and beef bones. When the gelatin does not easily dissolve, it may be dissolved by heating.

The volume of the reverse transcription reaction solution plug 47 is not particularly limited and can be appropriately set based on an index such as the amount of particles and the like onto which the nucleic acid has been adsorbed. For example, when inner diameter of the capillary is 1 mm, and the volume of the particles and the like is 0.5 μL, a volume of 0.6 μL or more is sufficient as the volume of the reverse transcription reaction solution plug 47. The volume is preferably from 0.8 μL to 5 μL, and more preferably from 1 μL to 3 μL. When the inner diameter of the capillary is smaller than the diameter described above, the volume of the reverse transcription reaction solution plug 47 may be set to be smaller than 0.6 μL. If the volume of the reverse transcription reaction solution plug 47 is within the above range, the reverse transcription reaction occurs to a sufficient degree even if the volume of the nucleic acid-binding solid-phase carriers is set to, for example, 0.5 μL.

The eluate contained in the eluate plug 49 refers to liquid that causes the nucleic acid, which has been adsorbed onto the nucleic acid-binding solid-phase carriers, to be eluted in to the liquid from the carriers. The solvent is not particularly limited and is preferably water or an aqueous solution with a low salt concentration. Moreover, it is preferable that the solvent substantially does not contain an organic solvent such as ethanol or isopropyl alcohol and a chaotropic substance. The aqueous with a low salt concentration is preferably a buffer. The salt concentration of the aqueous solution with a low salt concentration is preferably 100 mM or less, more preferably 50 mM or less, and most preferably 15 mM or less. The lower limit of the salt concentration of the aqueous solution with a low salt concentration is not particularly limited. However, the lower limit is preferably 0.1 mM or higher, more preferably 1 mM or higher, and most preferably 10 mM or higher. The salt for making the aqueous solution with a low salt concentration into a buffer is not particularly limited. However, salts of TRIS, HEPES, PIPES, phosphoric acid, and the like are preferably used, and among these, TE (10 mM TRIS-Cl buffer solution, 1 mM EDTA, pH 8.0) is most preferable.

The eluate may further contain a reagent for causing the nucleic acid amplification reaction. The reagent may contain a DNA polymerase, a primer (oligonucleotide) for a DNA polymerase, dNTP, a TaqMan probe, a probe for real time PCR, such as Molecular Beacon or a cycling probe, or a fluorescent dye for an intercalator such as SYBR green. The DNA polymerase is not particularly limited, but it is preferable to use heat-resistant enzymes or enzymes for PCR. For example, there are an extremely large number of commercially available products such as Taq polymerase, Tfi polymerase, Tth polymerase, and enzymes obtained by modifying the above enzymes. Moreover, it is preferable for the eluate to contain bovine serum albumin (BSA) or gelatin as a reaction hindrance inhibitor.

The concentration of dNTP or salt contained in the eluate may be set to a level suitable for the DNA polymerase to be used. However, generally, the concentration of dNTP is 10 μM to 1,000 μM and preferably 100 μM to 500 μM, the concentration of Mg²⁺ is preferably 1 mM to 100 mM and preferably 5 mM to 10 mM, and the concentration of Cl⁻ is 1 mM to 2,000 mM and preferably 200 mM to 700 mM. The total ion concentration is not particularly limited, but is preferably higher than 50 mM, more preferably higher than 100 mM, even more preferably higher than 120 mM, still more preferably higher than 150 mM, and yet more preferably higher than 200 mM. The upper limit thereof preferably 500 mM or less, more preferably 300 mM or less, and even more preferably 200 mM or less. The oligonucleotides for a primer are used at a concentration of 0.1 μM to 10 μM, and preferably at a concentration of 0.1 μM to 1 μM respectively. The reaction solution may contain BSA, gelatin, or the like as a carrier. If the concentration of BSA or gelatin is 1 mg/mL or less, the reaction hindrance inhibitory effect is diminished, and if the concentration is 10 mg/mL or higher, the polymerization reaction and the following enzyme reaction may be hindered. Accordingly, the concentration is preferably 1 mg/mL to 10 mg/mL. When gelatin is used, the source thereof is not particularly limited, and examples thereof include cowhide, pig hide, and beef bones. When the gelatin does not easily dissolve, it may be dissolved by heating.

The volume of the eluate plug 49 is not particularly limited and can be appropriately set based on an index such as the amount of particles and the like onto which the nucleic acid has been adsorbed. For example, when inner diameter of the capillary is 1 mm, and the volume of the particles and the like is 0.5 μL, a volume of 0.6 μL or more is sufficient as the volume of the eluate plug 49. The volume is preferably from 0.8 μL to 5 μL, and more preferably from 1 μL to 3 μL. When the inner diameter of the capillary is smaller than the diameter described above, the volume of the reverse transcription reaction solution plug 47 may be set to be smaller than 0.6 μL. If the volume of the eluate plug 49 is within the above range, the reverse transcription reaction occurs to a sufficient degree even if the volume of the nucleic acid-binding solid-phase carriers is set to, for example, 0.5 μL.

When the eluate does not contain the reagent for causing the nucleic acid amplification reaction, it is preferable to dispose the nucleic acid amplification reaction solution plug 50A, which contains the nucleic acid amplification reaction solution containing the reagent for causing the nucleic acid amplification reaction, and a fifth oil plug 50B in this order from a fourth oil plug 50, at the side of a fourth oil plug 50 close to the nucleic acid amplification reaction container (see FIG. 1C). Alternatively, instead of disposing the nucleic acid amplification reaction solution plug 50A and the fifth oil plug 50B, the PCR container 30 may contain a droplet of a nucleic acid amplification reaction solution that contains the reagent for causing the nucleic acid amplification reaction.

The solvent of the nucleic acid amplification reaction solution is not particularly limited and is preferably water or an aqueous solution with a low salt concentration. Moreover, it is preferable that the solvent substantially does not contain an organic solvent such as ethanol or isopropyl alcohol and a chaotropic substance. The aqueous with a low salt concentration is preferably a buffer. The salt concentration of the aqueous solution with a low salt concentration is preferably 100 mM or less, more preferably 50 mM or less, and most preferably 15 mM or less. The lower limit of the salt concentration of the aqueous solution with a low salt concentration is not particularly limited. However, the lower limit is preferably 0.1 mM or higher, more preferably 1 mM or higher, and most preferably 10 mM or higher. The salt for making the aqueous solution with a low salt concentration into a buffer is not particularly limited. However, salts of TRIS, HEPES, PIPES, phosphoric acid, and the like are preferably used, and among these, TE (10 mM TRIS-Cl buffer solution, 1 mM EDTA, pH 8.0) is most preferable.

The reagent for causing the nucleic acid amplification reaction may contain a DNA polymerase, a primer (oligonucleotide) for a DNA polymerase, dNTP, a TaqMan probe, a probe for real time PCR, such as Molecular Beacon or a cycling probe, or a fluorescent dye for intercalator such as SYBR green. The DNA polymerase is not particularly limited, but it is preferable to use heat-resistant enzymes or enzymes for PCR. For example, there are an extremely large number of commercially available products such as Taq polymerase, Tfi polymerase, Tth polymerase, and enzymes obtained by modifying the above enzymes. Moreover, it is preferable for the reagent to contain bovine serum albumin (BSA) or gelatin as a reaction hindrance inhibitor.

The concentration of dNTP or salt contained in the nucleic acid amplification reaction solution may be set to a level suitable for the DNA polymerase to be used. However, generally, the concentration of dNTP is 10 μM to 1,000 μM and preferably 100 μM to 500 μM, the concentration of Mg²⁺ is preferably 1 mM to 100 mM and preferably 5 mM to 10 mM, and the concentration of Cl⁻ is 1 mM to 2,000 mM and preferably 200 mM to 700 mM. The total ion concentration is not particularly limited, but is preferably higher than 50 mM, more preferably higher than 100 mM, even more preferably higher than 120 mM, still more preferably higher than 150 mM, and yet more preferably higher than 200 mM. The upper limit thereof is preferably 500 mM or less, more preferably 300 mM or less, and even more preferably 200 mM or less. The oligonucleotides for a primer are used at a concentration of 0.1 μM to 10 μM, and preferably at a concentration of 0.1 μM to 1 μM respectively. The nucleic acid amplification reaction solution may contain BSA, gelatin, or the like as a carrier. If the concentration of BSA or gelatin is 1 mg/mL or less, the reaction hindrance inhibitory effect is diminished, and if the concentration is 10 mg/mL or higher, the polymerization reaction and the following enzyme reaction may be hindered. Accordingly, the concentration is preferably 1 mg/mL to 10 mg/mL. When gelatin is used, the source thereof is not particularly limited, and examples thereof include cowhide, pig hide, and beef bones. When the gelatin does not easily dissolve, it may be dissolved by heating.

The volume of the nucleic acid amplification reaction solution plug 50A is not particularly limited and can be appropriately set based on an index such as the amount of particles and the like onto which the nucleic acid has been adsorbed. For example, when inner diameter of the capillary is 1 mm, and the volume of the particles and the like is 0.5 μL, a volume of 0.6 μL or more is sufficient as the volume of the nucleic acid amplification reaction solution plug 50A. The volume is preferably from 0.8 μL to 5 μL, and more preferably from 1 ill to 3 μL. When the inner diameter of the capillary is smaller than the diameter described above, the volume of reverse transcription reaction solution plug 47 may be set to be smaller than 0.6 μL.

The cartridge may further have a third washing solution plug 48A formed of a third washing solution that undergoes phase separation when being mixed with oil and washes the nucleic acid-binding solid-phase carriers having bound to the nucleic acid and a sixth oil plug 48B formed of a six oil in this order from the side of the third oil plug 48, between the third oil plug 48 and the eluate plug 49 (FIG. 1C).

The third washing solution plug 48A may be formed of a 5 mM TRIS-Cl buffer solution as the third washing solution. The third washing solution may be basically constituted in the same manner as the first washing solution, or may be the same as or different from the first washing solution. However, it is preferable for the third washing solution to be a solution that substantially does not contain a chaotropic substance. As described above, it is preferable for the third washing solution to contain alcohol in such an amount that does not hinder the adsorption of the nucleic acid onto carriers, the reverse transcription reaction, the PCR reaction, and the like. In this case, the concentration of alcohol may be 10% or less, and is preferably 5% or less or 2% or less, more preferably 1% or less or 0.5% or less, and most preferably 0.2% or less or 0.1% or less.

If the plug 48A formed of a washing solution is disposed after the reverse transcription reaction solution plug 47 in this manner, particularly when the nucleic acid amplification reaction is caused in the eluate plug 49, the amount of the reverse transcription reaction solution mixed into the nucleic acid amplification reaction solution is reduced. As a result, this brings an effect of increasing the efficiency of the nucleic acid amplification reaction.

The downstream portion of the capillary 23 is inserted into the PCR container 30. As a result, plug in the tube 20 can be pushed to the PCR container 30 out of the tube 20.

Acyclic convexity of the outer wall of the capillary 23 comes into contact with the inner wall of the PCR container 30, whereby an upper seal portion is formed. Furthermore, the outer wall of the capillary 23 at the downstream side from the upper seal portion comes into contact with the inner wall of the PCR container 30, whereby a lower seal portion is formed. The upper seal portion and lower seal portion will be described later.

The tube 20 further has the fixing claw 25 and the guide plate 26. FIG. 4 is a view for illustrating the fixing claw 25, the guide plate 26, and the mounting portion 62.

The fixing claw 25 is a member for fixing the cartridge 1 to the mounting portion 62. When the cartridge 1 is inserted into the mounting portion 62 until the fixing claw 25 is hooked on, the cartridge 1 is fixed to a normal position of the mounting portion 62. In other words, when the cartridge 1 is in an abnormal position of the mounting portion 62, the fixing claw 25 is not hooked on the mounting portion 62.

The guide plate 26 is a member for guiding the cartridge 1 when the cartridge 1 is mounted on the mounting portion 62 of the PCR device 100. A guide rail 63A is formed in the mounting portion 62 of the PCR device 100. The cartridge 1 is inserted into and fixed to the mounting portion 62 while being guided along the guide rail 63A by the guide plate 26 of the tube 20. The cartridge 1 is long. However, since the cartridge 1 is inserted into the mounting portion 62 under the guidance of the guide plate 26, it is easy to fix the cartridge 1 to a normal position of the mounting portion 62.

The fixing claw 25 and the guide plate 26 are plate-like members protruding from the right and left of the capillary 23. When the magnetic beads 7 in the tube 20 are moved by using a magnet, the magnet is caused to approach the tube, in the direction perpendicular to the plate-like fixing claw 25 or guide plate 26. Accordingly, the distance between the magnet and the magnetic beads 7 in the tube 20 can be shortened. However, for shortening the distance between the magnet and the magnetic beads 7 in the tube 20, the fixing claw 25 and the guide plate 26 may have other shapes.

(2-3) PCR Container

FIGS. 5A and 5B are views for illustrating the periphery of the PCR container 30. FIG. 5A is a view for illustrating the initial state. FIG. 5B is a view for illustrating the state where the plunger 10 has been pushed. Hereinafter, FIGS. 2A to 2C will also be referred to for describing the PCR container 30.

The PCR container 30 is a container which receives the liquid pushed out of the tube 20 and accommodates the PCR solution 40 containing the eluate plug 49 during the thermal cycling process.

The PCR container 30 has a seal formation portion 31 and a flow path formation portion 35. The seal formation portion 31 is a portion in which the tube 20 has been inserted and which inhibits the oil, which overflows from the flow path formation portion 35, from leaking to the outside. The flow path formation portion 35 is placed at the downstream side from the seal formation portion 31 and forms a flow path through which the PCR solution 40 in the form of a droplet moves. The PCR container 30 is fixed to the tube 20 at two sites including an upper seal portion 34A and a lower seal portion 34B of the seal formation portion 31.

The seal formation portion 31 has an oil accommodating portion 32 and a stepped portion 33.

The oil accommodating portion 32 is a cylindrical portion and functions as a reservoir accommodating the oil that overflows from the flow path formation portion 35. There is a gap between the inner wall of the oil accommodating portion 32 and the outer wall of the capillary 23 of the tube 20, and this gap becomes an oil accommodating space 32A accommodating the oil that overflows from the flow path formation portion 35. The volume of the oil accommodating space 32A is larger than the volume in which the seal 12A of the plunger 10 slides in the lower syringe 22 of the tube 20.

The inner wall of the upstream side of the oil accommodating portion 32 comes into contact with the cyclic convexity of the tube 20, whereby the upper seal portion 34A is formed. The upper seal portion 34A is a seal that allows permeation of air while inhibiting the oil of the oil accommodating space 32A from leaking to the outside. In the upper seal portion 34A, a vent having such a size that does not allow the oil to leak due to the surface tension of the oil is formed. The vent of the upper seal portion 34A may be a gap between the convexity of the tube 20 and the inner wall of the oil accommodating portion 32, or may be a hole, groove, or notch formed in the convexity of the tube 20. Moreover, the upper seal portion 34A may be formed of an oil absorbent absorbing oil.

The stepped portion 33 is a portion which is disposed at the downstream side of the oil accommodating portion 32 and shows a step difference. The inner diameter of the downstream portion of the stepped portion 33 is smaller than the inner diameter of the oil accommodating portion 32. The inner wall of the stepped portion 33 comes into contact with the outer wall of the downstream side of the capillary 23 of the tube 20. The inner wall of the stepped portion 33 comes into contact with the outer wall of the tube 20, whereby the lower seal portion 34B is formed. The lower seal portion 34B is a seal that allows the oil of the flow path formation portion 35 to flow to the oil accommodating space 32A while exhibiting resistance to the flow. Due to pressure loss of the lower seal portion 34B, the pressure in the flow path formation portion 35 becomes higher than the outside pressure. Therefore, even if the liquid in the flow path formation portion 35 is heated during the thermal cycling process, air bubbles are not easily formed in the liquid in the flow path formation portion 35.

The flow path formation portion 35 is a tubular portion and functions as a container forming a flow path through which the PCR solution 40 in the form of a droplet moves. The flow path formation portion 35 is filled with oil. The upstream side of the flow path formation portion 35 is closed by the terminal of the tube 20, and the terminal of the tube 20 is opened toward the flow path formation portion 35. The inner diameter of the flow path formation portion 35 is larger than the inner diameter of the capillary 23 of the tube 20, and is also larger than the outer diameter of a sphere of the PCR solution 40 that has been made into a sphere. It is desirable for the inner wall of the flow path formation portion 35 to exhibit water repellency to such a degree that the water-soluble PCR solution 40 does not adhere to the inner wall.

The upstream side of the flow path formation portion 35 is heated at a relatively high temperature (for example, about 95° C.) by the high temperature-side heater 65B of the outside, thereby forming a high-temperature region 36A. The downstream side of the flow path formation portion 35 is heated at a relatively low temperature (for example, about 60° C.) by the low temperature-side heater 65C of the outside, thereby forming a low-temperature region 36B. The bottom 35A (edge of the downstream side) of the PCR container 30 includes the low-temperature region 36B. As a result, a temperature gradient is formed in the liquid in the flow path formation portion 35.

As shown in FIG. 5A, in the initial state, oil is filled in the flow path formation portion 35 of the PCR container 30. The interface of the oil is positioned at the relatively downstream side from the oil accommodating space 32A. In the oil accommodating space 32A, the volume of the upstream side from the interface of the oil is larger than the volume in which the seal 12A of the plunger 10 slides in the lower syringe 22 of the tube 20.

As shown in FIG. 5B, when the plunger 10 is pushed, the liquid in the tube 20 is pushed out into the flow path formation portion 35. Since the liquid in the tube 20 is pushed out into the flow path formation portion 35 which has already been filled with oil, gas does not flow into the flow path formation portion 35.

When the plunger 10 is pushed, first, the oil in the oil plugs (the fourth oil plug 50, the fifth oil plug 50B, and the like) that are in the lowermost portion of the downstream of the tube 20 flows into the flow path formation portion 35, the inflow oil then flows into the oil accommodating space 32A from the flow path formation portion 35, and the oil interface of the oil accommodating space 32A ascends. At this time, due to pressure loss of the lower seal portion 34B, the pressure of the liquid of the flow path formation portion 35 increases. After the oil at the lowermost side is pushed out of the tube 20, the solution in the second plugs (the eluate plug 49, the nucleic acid amplification reaction solution plug 50A, and the like) from the lowermost portion of the downstream flows into the flow path formation portion 35 from the tube 20. When the second plug from the lowermost portion of the downstream, such as the eluate plug 49, contains a nucleic acid to be amplified and the reagent for causing the nucleic acid amplification reaction, the inflow solution directly becomes the PCR solution 40 in the forms of a droplet. When the cartridge has the nucleic acid amplification reaction solution plug 50A or the like, and the nucleic acid to be amplified and the reagent for causing the nucleic acid amplification reaction are contained in another plug, the plunger 10 is pushed until those two plugs flow into the flow path formation portion. Since the inner diameter of the flow path formation portion 35 is larger than the inner diameter of the capillary 23, those two plugs (for example, the eluate plug 49 and the nucleic acid amplification reaction solution plug 50A) that have been in the form of a plug (column) inside the tube 20 are mixed with each other in the oil of the flow path formation portion 35, whereby the PCR solution 40 in the form of a droplet is formed. When the PCR container 30 has a droplet of the nucleic acid amplification reaction solution that undergoes phase separation when being mixed with oil and contains the reagent for causing the nucleic acid amplification reaction, the inflow eluate is mixed with the droplet of the nucleic acid amplification reaction solution in the oil of the flow path formation portion 35, whereby the PCR solution 40 in the forms of a droplet is formed. Moreover, in the initial state, the volume of the oil accommodating space 32A that is at the upstream side from the interface of the oil is larger than the volume in which the seal 12A of the plunger 10 slides in the lower syringe 22 of the tube 20. Consequently, the oil does not overflow from the oil accommodating space 32A.

PCR Device 100

FIG. 6A is a perspective view showing the internal constitution of the PCR device 100. FIG. 6B is a lateral view showing the main constitution of the PCR device 100. FIG. 7 is a block diagram of the PCR device 100. The PCR device 100 is a device performing nucleic acid elution process and thermal cycling process by using the cartridge 1.

Hereinafter, the meaning of “upper and lower”, “front and back”, and “left and right” will be defined as shown in the drawings to describe the PCR device 100. When a base 51 of the PCR device 100 is horizontally disposed, a direction perpendicular to the base 51 is defined as “vertical direction”, and “upper” and “lower” will be defined according to the direction of gravity. Moreover, the axial direction of the rotary shaft of the cartridge 1 is defined as “horizontal direction”, and a direction perpendicular to the vertical direction and the horizontal direction is defined as “front-back direction”. When the PCR device is viewed from the rotary shaft of the cartridge 1, the side of a cartridge insertion port 53A is defined as “back”, and the side opposite to the “back” is defined as “front”. When the PCR device is viewed from the front side, the right side and left side in the horizontal direction are defined as “right” and “left” respectively.

The PCR device 100 has a rotation mechanism 60, a magnet moving mechanism 70, a pushing mechanism 80, the fluorescence measuring instrument 55, and a controller 90.

(1) Rotation Mechanism 60

The rotation mechanism 60 is a mechanism for rotating the cartridge 1 and heaters. When the cartridge 1 and heaters become upside down by the rotation mechanism 60, the PCR solution 40 in the form of a droplet moves inside the flow path formation portion 35 of the PCR container 30, whereby thermal cycling process is performed.

The rotation mechanism 60 has a rotary body 61 and a motor for rotation 66. FIG. 8A is a view for illustrating the rotary body 61. FIG. 8B is a view for illustrating the state where the cartridge 1 has been mounted on the mounting portion 62 of the rotary body 61.

The rotary body 61 is a member that can rotate around the rotary shaft. The rotary shaft of the rotary body 61 is supported on a support 52 fixed to the base 51. The rotary body 61 is provided with the mounting portion 62 onto which the cartridge 1 is mounted and heaters (the heater for elution 65A, the high temperature-side heater 65B, the low temperature-side heater 65C, and the like). When the rotary body 61 rotates, the cartridge 1 can become upside down in a state where the positional relationship between the cartridge 1 and the heaters is maintained. The motor for rotation 66 is a source of power for rotating the rotary body 61. According to the instruction from the controller 90, the motor for rotation 66 causes the rotary body 61 to rotate to a predetermined position. A transmission mechanism such as a gear may be disposed between the motor for rotation 66 and the rotary body 61.

The mounting portion 62 is a portion on which the cartridge 1 is mounted. The mounting portion 62 has a fixing portion 63 in which a notch is formed. Moreover, an insertion hole 64A formed in the heaters (the heater for elution 65A, the high temperature-side heater 65B, the low temperature-side heater 65C, and the like) also functions as the mounting portion 62. When the fixing claw 25 of the cartridge 1 is hooked on the notch of the fixing portion 63 in a state where the PCR container 30 has been inserted into the insertion hole 64A, the cartridge 1 is mounted on the rotary body 61 (see FIG. 4). Herein, a portion of the heaters also functions as the mounting portion 62, but the mounting portion 62 may be separated from the heaters. The mounting portion 62 is indirectly fixed to the rotary body 61 through the heater for elution 65A. However, the mounting portion 62 may be directly disposed in the rotary body 61. Moreover, the number of the cartridge 1 that can be mounted on the mounting portion 62 is not limited to one, and plural cartridges 1 may be mounted on the mounting portion 62.

The guide rail 63A is formed in the fixing portion 63 along the vertical direction (see FIG. 4). The guide rail 63A guides the guide plate 26 of the cartridge 1 in the insertion direction while restraining the guide plate 26 in the front-back direction. While the guide plate 26 is being guided by the guide rail 63A, the cartridge 1 is inserted into the mounting portion 62. Consequently, the PCR container 30 of the cartridge 1 is guided to the insertion hole 64A, whereby the cartridge 1 is fixed to a normal position of the mounting portion 62.

The PCR device 100 has heater such as the high temperature-side heater 65B and low temperature-side heater 65C, which are heaters for PCR, and the heater for elution 65A. Each of the heaters is constituted with heating source not shown in the drawing and a heat block. The heating source is, for example, a cartridge heater and has been inserted into the heat block. The heat block is, for example, a metal with high heat conductivity, such as aluminum, and heats the liquid in the cartridge 1 with the heat from the heating source while suppressing heat unevenness. It is desirable for the heat block to be a nonmagnetic substance to prevent the magnets 71, which moves the magnetic beads 7, from being adsorbed onto the heat block.

The heater for elution 65A is a heater that heats the reverse transcription reaction solution plug 47 and the eluate plug 49 of the cartridge 1. When the cartridge 1 is fixed to a normal position, the heater for elution 65A faces the reverse transcription reaction solution plug 47 or the eluate plug 49 of the tube 20. For example, the heater for elution 65A heats the reverse transcription reaction solution plug 47 to about 45° C. or heats the eluate plug 49 to about 50° C., whereby liberation of the nucleic acid from the magnetic beads is accelerated. Moreover, as a heater that heats the reverse transcription reaction solution plug 47, a heater for reverse transcription reaction may be provided independently of the heater for elution 65A that heats the eluate plug 49, and the overall constitution of the heaters is not particularly limited.

The high temperature-side heater 65B is a heater that heats the upstream side of the flow path formation portion 35 of the PCR container 30. When the cartridge 1 is fixed to a normal position, the high temperature-side heater 65B faces the upstream side (high-temperature region 36A) of the flow path formation portion 35 of the PCR container 30. For example, the high temperature-side heater 65B heats the liquid of the upstream side of the flow path formation portion 35 of the PCR container 30 to about 90° C. to 100° C.

The low temperature-side heater 65C is a heater that heats the bottom 35A of the flow path formation portion 35 of the PCR container 30. When the cartridge 1 is fixed to a normal position, the low temperature-side heater 65C faces the downstream side (the low-temperature region 36B) of the flow path formation portion 35 of the PCR container 30. For example, the low temperature-side heater 65C heats the liquid in the low-temperature region 36B of the PCR container 30 to about 50° C. to 75° C.

A spacer 65D is disposed between the high temperature-side heater 65B and the low temperature-side heater 65C. The spacer 65D suppresses heat conduction caused between the high temperature-side heater 65B and the low temperature-side heater 65C. The spacer 65D is also used for accurately setting the distance between the high temperature-side heater 65B and the low temperature-side heater 65C. In this manner, by the high temperature-side heater 65B and the low temperature-side heater 65C, a temperature gradient is formed in the liquid in the flow path formation portion 35 of the PCR container 30.

In each of the heat blocks constituting each of the heater for elution 65A, high temperature-side heater 65B, and low temperature-side heater 65C, a through hole constituting the insertion hole 64A is formed. The outer wall of the bottom 35A of the PCR container 30 is exposed through the opening of the lower side of the insertion hole 64A of the low temperature-side heater 65C. The fluorescence measuring instrument 55 measures luminance of the PCR solution 40 present at the bottom 35A of the PCR container 30 from the opening of the lower side of the insertion hole 64A. The fluorescence measuring instrument 55 may have constitution that can detect luminance of plural wavelength regions, such that the PCR device can be used for multiplex PCR.

Each of the high temperature-side heater 65B and the low temperature-side heater 65C is provided with a temperature control device. Accordingly, the temperature can be set to a level suitable for each polymerase reaction.

(2) Magnet Moving Mechanism 70

The magnet moving mechanism 70 is a mechanism moving the magnets 71. The magnet moving mechanism 70 causes the magnetic beads 7 in the cartridge 1 to be attracted to the magnets 71 and moves the magnets 71 such that the magnetic beads 7 move in the inside of the cartridge 1. The magnet moving mechanism 70 has a pair of magnets 71, an elevating mechanism 73, and a oscillation mechanism 75.

The magnets 71 are members attracting the magnetic beads 7. As the magnets 71, a permanent magnet, an electromagnet, and the like can be used. However, herein, a permanent magnet that does not generate heat or the like is used. The pair of magnets 71 is held in an arm 72 while facing each other in the front-back direction, in a state where the position thereof in the vertical direction is almost the same. The respective magnets 71 can face each other at the front side or the back side of the cartridge 1 mounted on the mounting portion 62. The pair of magnets 71 can sandwich the cartridge 1 mounted on the mounting portion 62 therebetween in the front-back direction. If the magnets 71 are caused to face each other in a direction (herein, front-back direction) orthogonal to the direction (herein, horizontal direction) in which the fixing claw 25 or the guide plate 26 of the cartridge 1 is disposed, the distance between the magnetic beads 7 in the cartridge 1 and the magnets 71 can be shortened.

The elevating mechanism 73 is a mechanism for moving the magnets 71 in the vertical direction. Since the magnets 71 attract the magnetic beads 7, if the magnets 71 are moved in the vertical direction in accordance with the movement of the magnetic beads 7, the magnetic beads 7 in the cartridge 1 can be attracted in the vertical direction.

The elevating mechanism 73 has a carriage 73A moving in the vertical direction and a motor for elevation 73B. The carriage 73A is a member movable in the vertical direction. By a carriage guide 73C disposed in a lateral wall 53 where the cartridge insertion port 53A is placed, the carriage 73A is guided so as to be movable in the vertical direction. The arm 72 holding the pair of magnets 71 is mounted on the carriage 73A. Accordingly, when the carriage 73A moves in the vertical direction, the magnets 71 also move in the vertical direction. The motor for elevation 73B is a source of power for moving the carriage 73A in the vertical direction. According to the instruction from the controller 90, the motor for elevation 73B moves the carriage 73A to a predetermined position in the vertical direction. The motor for elevation 73B moves the carriage 73A in the vertical direction by using a belt 73D and a pulley 73E. However, the motor for elevation 73B may move the carriage 73A in the vertical direction by using other transmission mechanisms.

When the carriage 73A is in the uppermost position (retraction position), the magnets 71 are positioned above the cartridge 1. When the carriage 73A is in the retraction position, the elevating mechanism 73 does not come into contact with the cartridge 1 even if the cartridge 1 rotates. The elevating mechanism 73 can bring down the carriage 73A to a position where the magnets 71 face the reaction plug. Therefore, the elevating mechanism 73 can move the magnets 71 such that the magnetic beads 7 in the tank 3 move to the position of the reaction plug.

The oscillation mechanism 75 is a mechanism for causing the pair of magnets 71 to oscillate in the front-back direction. When the pair of magnets 71 is caused to oscillate in the front-back direction, each of the magnets 71 becomes distant from the cartridge 1 by different length. Since the magnetic beads 7 are attracted to the magnets 71 close to the cartridge 1, if the pair of magnets 71 is caused to oscillate in the front-back direction, the magnetic beads 7 in the cartridge 1 move in the front-back direction.

The oscillation mechanism 75 has a motor for oscillation 75A and a gear. The motor for oscillation 75A and the gear are disposed in the carriage 73A and can move in the vertical direction together with the carriage 73A. When the power of the motor for oscillation 75A is transmitted to the arm 72 through the gear, the arm 72 holding the magnets 71 rotates around an oscillating rotary shaft 75B relative to the carriage 73A. In order to prevent damage of the cartridge 1 that is caused by contact between the magnets 71 and the cartridge 1, the oscillation mechanism 75 causes the magnets 71 to oscillate within a range in which the magnets 71 do not come into contact with the cartridge 1.

The oscillating rotary shaft 75B is a rotary shaft of the arm 72. The oscillating rotary shaft 75B is in parallel with the horizontal direction so as to be able to cause the magnets 71 to oscillate in the front-back direction. When being viewed from the right or left, the oscillating rotary shaft 75B is disposed in a position that departs from the cartridge 1 toward the front or back of the cartridge. Therefore, when the carriage 73A moves to the lower side, the contact between the cartridge 1 and the arm 72 can be avoided. If the magnets 71 can be caused to oscillate in the front-back direction, the oscillating rotary shaft 75B may be a shaft that is in parallel with the vertical direction.

(3) Pushing Mechanism 80

The pushing mechanism 80 is a mechanism for pushing the plunger 10 of the cartridge 1. When the plunger 10 is pushed by the pushing mechanism 80, the plugs such as the eluate plug 49 and oil plugs of the cartridge 1 are pushed out to the PCR container 30, whereby the PCR solution 40 in the form of a droplet is formed in the oil of the PCR container 30.

The pushing mechanism 80 has a motor for a plunger 81 and a rod 82. The motor for a plunger 81 is a source of power for moving the rod 82. The rod 82 is a member for pushing the mounting board 11A of the plunger 10 of the cartridge 1. The reason why the mounting board 11A is pushed instead of the tank 3 of the cartridge 1 is that the tank 3 is constituted with a flexible resin that can dilate. When the tank 3 is not deformed, the pushing mechanism 80 may push the tank 3 to push the plunger 10.

The plunger 10 is pushed by the rod 82, not in the vertical direction but in a direction that inclines from the vertical direction by 45°. Accordingly, when the plunger 10 is pushed by the pushing mechanism 80, in the PCR device 100, the rotary body 61 is caused to rotate by 45° to match the longitudinal direction of the cartridge 1 with the movement direction of the rod 82, and then the rod 82 is moved. Since the rod 82 pushes the plunger 10 in the direction that inclines from the vertical direction by 45°, it is easy to dispose the pushing mechanism 80 such that this mechanism becomes free from interference of the elevating mechanism 73. Moreover, since the rod 82 pushes the plunger 10 in the direction that inclines from the vertical direction by 45°, the size of the PCR device 100 can be reduced in the vertical direction.

(4) Fluorescence Measuring Instrument 55

The fluorescence measuring instrument 55 is an instrument for measuring luminance of the PCR solution 40 of the PCR container 30. The fluorescence measuring instrument 55 is disposed below the rotary body 61 so as to face the bottom 35A of the PCR container 30 of the cartridge 1. The fluorescence measuring instrument 55 measures luminance of the PCR solution 40 present in the bottom 35A of the PCR container 30 from the opening of the lower side of the insertion hole 64A of the low temperature-side heater 65C.

(5) Controller 90

The controller 90 is a portion for controlling the PCR device 100. The controller 90 has, for example, a processor such as CPU and a memory such as ROM or RAM. In the memory, various programs and data are stored. Moreover, the memory provides a region for running the programs. When the processor executes the program stored in the memory, various types of process are performed.

For example, the controller 90 controls the motor for rotation 66 to rotate the rotary body 61 to a predetermined rotation position. The rotation mechanism 60 is provided with a rotation position sensor not shown in the drawing, and the controller 90 drives and stops the motor for rotation 66 in response to the results detected by the rotation position sensor.

Furthermore, the controller 90 controls the heaters (heater for elution 65A, high temperature-side heater 65B, low temperature-side heater 65C, and the like) such that each heater generates heat. The heat block constituting the heaters is provided with a temperature sensor not shown in the drawing. The controller 90 controls ON and OFF of the cartridge heater in response to the results detected by the temperature sensor.

In addition, the controller 90 controls the motor for elevation 73B to move the magnets 71 in the vertical direction. The PCR device 100 is provided with a position sensor not shown in the drawing that detects the position of the carriage 73A. The controller 90 drives and stops the motor for elevation 73B in response to the results detected by the position sensor.

Moreover, the controller 90 controls the motor for oscillation 75A to cause the magnets 71 to oscillate in the front-back direction. The PCR device 100 is provided with a position sensor that detects the position of the arm 72 holding the magnets 71. The controller 90 drives and stops the motor for oscillation 75A in response to the results detected by the position sensor.

The controller 90 controls the fluorescence measuring instrument 55 to measure luminance of the PCR solution 40 of the PCR container 30. When the fluorescence measuring instrument 55 faces the bottom 35A of the PCR container 30 of the cartridge 1, the controller 90 controls the fluorescence measuring instrument 55 to measure the luminance. The measurement results are stored in the memory.

Description of Operation
(1) Operation for Mounting Cartridge 1

FIGS. 9A to 9D are views for illustrating the state of the PCR device 100 at the time of mounting the cartridge 1. FIG. 9A is a view for illustrating an initial state where the cartridge 1 has not yet been mounted. FIG. 9B is a view for illustrating a stand-by state. FIG. 9C is a view for illustrating the state where the cartridge 1 has just been mounted. FIG. 9D is a view for illustrating an initial state in the state where the cartridge 1 has been mounted.

As shown in FIG. 9A, in the initial state where the cartridge 1 has not yet been mounted, the mounting direction of the mounting portion 62 is in the vertical direction. In the following description, the rotation position of the rotary body 61 in this state is taken as a standard (0°), and if the rotary body 61 rotates in a counter clockwise direction when viewed from the right, the direction is regarded as being a positive direction to describe the rotation position of the rotary body 61.

As shown in FIG. 9B, the controller 90 drives the motor for rotation 66 to rotate the rotary body 61 by −30°. In this state, an operator inserts the cartridge 1 into the mounting portion 62 from the cartridge insertion port 53A. At this time, since the cartridge 1 is inserted into the mounting portion 62 while the guide plate 26 is being guided by the guide rail 63A, the PCR container 30 of the cartridge 1 is guided to the insertion hole 64A of the mounting portion 62. The operator inserts the cartridge 1 until the fixing claw 25 of the cartridge 1 is hooked on the notch of the fixing portion 63. In this manner, the cartridge 1 is fixed to a normal position of the mounting portion 62. When the PCR container is not inserted into the insertion hole 64A, and the cartridge 1 is fixed to an abnormal position of the mounting portion 62, the fixing claw 25 of the cartridge 1 is not hooked on the notch of the fixing portion 63. Accordingly, the operator can see the cartridge 1 is in an abnormal position.

As shown in FIG. 9C, when the cartridge 1 is fixed to a normal position of the mounting portion 62, the eluate plug 49 of the tube 20 faces the heater for elution 65A, the upstream side (high-temperature region 36A) of the flow path formation portion 35 of the PCR container 30 faces the high temperature-side heater 65B, and the downstream side (low-temperature region 36B) of the flow path formation portion 35 of the PCR container 30 faces the low temperature-side heater 65C. Since the mounting portion 62 and the heaters are disposed in the rotary body 61, even when the rotary body 61 rotates, the positional relationship between the cartridge 1 and the heaters is maintained in this state.

After the cartridge 1 is mounted on the mounting portion 62, the controller 90 controls the rotary body 61 to rotate by 30° as shown in FIG. 9D such that the rotary body 61 returns to the standard position. The controller 90 may detect the state where the cartridge 1 has been mounted on the mounting portion 62 by using a sensor not shown in the drawing. Alternately, the controller 90 may detect the state by input operation performed by the operator.

(2) Nucleic Acid Elution Process
Vertical Movement of Magnets 71

FIG. 10 is a schematic view showing the behavior of the magnetic beads 7 at the time when the magnets 71 are vertically moved. The magnetic beads 7 in the cartridge 1 are attracted to the magnets 71. Accordingly, when the magnets 71 move at the outside of the cartridge 1, the magnetic beads 7 in the cartridge 1 also move along with the magnets 71.

FIGS. 11A to 11C are views for illustrating nucleic acid elution process. FIG. 11A is a view for illustrating the state of the PCR device 100 in which the nucleic acid elution process has not yet been performed. FIG. 11B is a view for illustrating the state of the PCR device 100 in which the magnets 71 have been moved to the eluate plug 49. FIG. 11C is a view for illustrating the state of the PCR device 100 in which the magnets 71 have been drawn up.

As shown in FIG. 11A, in the initial state, the tank becomes the upper side of the cartridge 1, and the longitudinal direction of the cartridge 1 is in parallel with the vertical direction. In this state, as shown in FIG. 2A, the cartridge 1 has the lysing solution 41 (tank 3) containing the magnetic beads 7, the oil 42 (plunger 10), the first washing solution 43 (upstream side of the tube 20), the first oil plug (capillary 23), the second washing solution plug 45 (capillary 23), the second oil plug 46 (capillary 23), the reverse transcription reaction solution plug 47 (capillary 23), the third oil plug 48 (capillary 23), the eluate plug 49 (capillary 23), the fourth oil plug 50 (capillary 23), and oil (PCR container 30) in this order from the upper side of the cartridge.

As shown in FIG. 11A, in the initial state, the carriage 73A is in the uppermost position (retraction position), and the magnets 71 are placed above the cartridge 1. In this state, the controller 90 drives the motor for elevation 73B to slowly move downward the carriage 73A such that the magnets 71 slowly move downward. Since the longitudinal direction of the cartridge 1 is in parallel with the vertical direction of the PCR device 100, the magnets 71 move along the cartridge 1.

When the magnets 71 move downward, the magnets 71 face the tank 3, and the magnetic beads 7 in the tank 3 are attracted to the magnets 71. The controller 90 moves downward the carriage 73A at such a speed that enables the magnetic beads 7 to move together with the magnets 71.

When the magnets 71 move from the position (the height of the tank 3) facing the tank 3 to the position (the height of the plunger 10) facing the plunger 10, the magnetic beads 7 pass through the opening of the upstream side of the cylindrical portion 11 of the plunger 10 and then pass through the interface between the lysing solution 41 in the tank 3 and the oil 42 of the upstream side of the cartridge main body 9. As a result, the magnetic beads 7 having bound to the nucleic acid are introduced into the cartridge main body 9. When the magnetic beads 7 pass through the interface between the lysing solution 41 and the oil 42, the lysing solution 41 is wiped by the oil 42. Consequently, the components of the lysing solution 41 are not easily brought into the oil 42. As a result, it is possible to prevent the components of the lysing solution 41 from being mixed into the washing solution, the reverse transcription reaction solution 47, or the eluate plug 49.

When the magnets 71 move downward in the state of facing the plunger 10, the magnetic beads 7 pass through the inside of the cylindrical portion 11, escape from the inside and outside of the ribs 13, come out of the opening of the downstream side of the cylindrical portion 11, and are introduced into the upper syringe 21 of the tube 20. Meanwhile, the magnetic beads 7 pass through the interface between the oil 42 and the first washing solution 43, in the plunger 10. When the magnetic beads 7 are introduced into the first washing solution 43, the nucleic acid having bound to the magnetic beads 7 is washed with the first washing solution 43.

At this stage, the rod-like portion 12 of the plunger 10 has not yet been inserted into the lower syringe 22 of the tube 20. Accordingly, when the magnets 71 move from the position (the height of the upper syringe 21) facing the upper syringe 21 to the position (the height of the capillary 23) facing the capillary 23, the magnetic beads 7 move to the lower syringe 22 from the upper syringe 21 and then move to the capillary 23 from the lower syringe 22. The first oil plug 44 is at the upstream side of the capillary 23, and when the magnetic beads 7 move to the capillary 23 from the lower syringe 22, the magnetic beads 7 pass through the interface between the first washing solution 43 and the oil. At this time, since the first washing solution 43 is wiped by the oil, the components of the first washing solution 43 are not easily brought into the oil. In this manner, it is possible to prevent the components of the first washing solution 43 from being mixed into the second washing solution plug 45, the reverse transcription reaction solution plug 47, or the eluate plug 49.

When the magnets 71 move from the position (the height of the first oil plug 44) facing the first oil plug 44 to the position (the height of the second washing solution plug 45) facing the second washing solution plug 45, the magnetic beads 7 pass through the interface between the first oil plug 44 and the second washing solution plug 45. When the magnetic beads 7 are introduced into the second washing solution plug 45, the nucleic acid having bound to the magnetic beads 7 is washed with the washing solution.

When the magnets 71 move from the position (the height of the second washing solution plug 45) facing the second washing solution plug 45 to the position (the height of the second oil plug 46) facing the second oil plug 46, the magnetic beads 7 pass through the interface between the second washing solution plug 45 and the second oil plug 46. At this time, since the washing solution is wiped by oil, the components of the washing solution are not easily brought into the oil. In this manner, it is possible to prevent the components of the washing solution from being mixed into the reverse transcription reaction solution plug 47.

When the magnets 71 move from the position (the height of the second oil plug 46) facing the second oil plug 46 to the position (the height of the reverse transcription reaction solution plug 47) facing the reverse transcription reaction solution plug 47, the magnetic beads 7 pass through the interface between the oil and the reverse transcription reaction solution 47.

Before the magnetic beads 7 are introduced into the reverse transcription reaction solution plug 47, the controller 90 controls the heater for elution 65A to heat the reverse transcription reaction solution plug 47 to about 45° C. Moreover, if the reverse transcription reaction solution 47 is heated before the magnetic beads 7 are introduced into the reverse transcription reaction solution 47, the time from when the magnetic beads 7 are introduced into the reverse transcription reaction solution 47 to when the reverse transcription is completed can be shortened.

After the magnets 71 move to the position (the height of the reverse transcription reaction solution plug 47) facing the reverse transcription reaction solution plug 47, the controller 90 stops the motor for elevation 73B to stop the vertical movement of the magnets 71, and then the reverse transcription reaction solution plug 47 is heated at 45° C. for 30 seconds, the reverse transcription reaction of the nucleic acid having bound to the magnetic beads 7 is caused.

When the magnets 71 move from the position (the height of the reverse transcription reaction solution plug 47) facing the reverse transcription reaction solution plug 47 to the position (the height of the third oil plug 48) facing the third oil plug 48, the magnetic beads 7 pass through the interface between the reverse transcription reaction solution plug and oil. At this time, since the reverse transcription reaction solution plug is wiped by the oil, the components of the reverse transcription reaction solution plug are not easily brought into the oil. As a result, it is possible to inhibit the components of the reverse transcription reaction solution plug from being mixed into the eluate plug 49.

When the magnets 71 move from the position (the height of the third oil plug 48) facing the third oil plug 48 to the position (the height of the eluate plug 49) facing the eluate plug 49, the magnetic beads 7 pass through the interface between oil and the eluate plug 49.

Before the magnetic beads 7 are introduced into the eluate plug 49, the controller 90 controls the heater for elution 65A to heat beforehand the eluate plug 49 at about 50°. If the eluate 49 is heated in advance before the magnetic beads 7 are introduced into the eluate 49, the time from when the magnetic beads 7 are introduced into the eluate 49 to when the elution of the nucleic acid is completed can be shortened.

As shown in FIG. 11B, after the magnets 71 move to the position (the height of the eluate plug 49) facing the eluate plug 49, the controller 90 stops the motor for elevation 73B to stop the vertical movement of the magnets 71, and heats the eluate plug 49 at 50° C. for 30 seconds. As a result, the nucleic acid having bound to the magnetic beads 7 is liberated into the eluate plug 49. If the reaction solution 47 is heated, the elution of the nucleic acid from the magnetic beads 7 is accelerated.

After the nucleic acid is eluted in the eluate plug 49, the controller 90 drives the motor for elevation 73B in a direction opposite to the direction in which the motor has been driven, such that the carriage 73A slowly moves upward and the magnets 71 also slowly move upward. The controller 90 moves the carriage 73A upward at such a speed that makes the magnetic beads 7 move together with the magnets 71.

When the magnets 71 move upward in the state shown in FIG. 11B, the magnetic beads 7 move to the second oil plug 46 from the eluate plug 49, whereby the magnetic beads 7 are removed from the eluate plug 49.

When the magnets 71 slowly move to the position facing the upper syringe 21, the magnetic beads 7 also move to the upper syringe 21 and are positioned above the lower syringe 22. If moved to such a position, the magnetic beads 7 are never introduced into the PCR container 30 when the plunger 10 is pushed. Therefore, while the state of the PCR device 100 is being changed to the state shown in FIG. 11C from the state described above, the controller 90 may move the carriage 73A upward at such a speed that inhibits the magnetic beads 7 from following the movement of the magnets 71. In addition, if the magnetic beads 7 are not introduced into the PCR container 30 when the plunger 10 is pushed, the movement speed of the carriage 73A may be increased at the earlier stage.

The memory of the controller 90 stores information regarding the movement speed of the magnets 71. The controller 90 executes the above operation (operation for causing the magnets 71 to move up and down) according to the information.

Oscillation of Magnets 71

While the magnets 71 are being moved vertically, the controller 90 may drive the motor for oscillation 75A such that the pair of magnets 71 sandwiching the cartridge 1 therebetween oscillates in the front-back direction.

FIG. 12 is a schematic view showing the behavior of the magnetic beads 7 at the time when the magnets 71 are caused to oscillate.

While the magnets 71 are moving in the vertical direction, the tube 20 is interposed between the pair of magnets 71 in the front-back direction. Since the pair of magnets 71 is held by the arm 72, the distance between the pair of magnets 71 in the front-back direction is almost constant. Therefore, one of the pair of magnets 71 approaches the tube 20, the other magnet is separated from the tube 20.

The magnetic beads 7 are attracted to the magnet 71 close to the magnetic beads. Accordingly, when one of the pair of magnets 71 approaches the tube 20, the magnetic beads 7 are attracted to the approaching magnet 71. Thereafter, when the above magnet 71 is separated from the tube 20, and then the other magnet 71 approaches the tube 20, the magnetic beads 7 are attracted to the approaching magnet 71. In this manner, the magnetic beads 7 move in the front-back direction. When the pair of magnets 71 is caused to oscillate in the front-back direction, the magnetic beads 7 reciprocate in the front-back direction.

When the magnetic beads 7 reciprocate in the front-back direction, the magnetic beads 7 easily come into contact with liquid. Particularly, since the liquid in the capillary 23 practically does not exhibit fluidity, when it is desired to make the liquid in the capillary 23 become close to the magnetic beads 7 as much as possible, it is effective to cause the magnetic beads 7 to reciprocate in the front-back direction.

FIG. 13 is a table showing whether or not the magnets 71 oscillate.

When the magnetic beads 7 move the oil plug (the first oil plug 44, the second oil plug 46, or the third oil plug 48) downward, the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. At this time, the controller 90 moves the magnets 71 downward, in a state where one of the pair of magnets 71 has been brought close to the tube 20. This is because the magnetic beads 7 more easily follow the movement of the magnets 71, compared to the case where the respective magnets 71 are separated from the tube 20 by the same distance.

When the magnetic beads 7 move the second washing solution plug 45 downward, the controller 90 drives the oscillation motor to cause the magnets 71 to oscillate in the front-back direction. As a result, the magnetic beads 7 move downward while oscillating in the front-back direction inside the second washing solution plug 45, hence the washing effect of the magnetic beads 7 can be enhanced. Moreover, since the washing effect is enhanced, the amount of the second washing solution plug 45 can be reduced, and the cartridge 1 can be miniaturized.

When the magnetic beads 7 pass through the interface between the washing solution and oil (second oil plug 46), the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. In this manner, since the magnetic beads 7 do not oscillate when passing through the interface, the components of the washing solution are not easily brought into the oil. Moreover, the controller 90 moves the magnets 71 downward, in a state where one of the pair of magnets 71 is brought close to the tube 20. As a result, the magnetic beads 7 close to the magnet 71 are attracted to the magnet and are aggregated, and the washing solution having adhered to the magnetic beads 7 is squeezed out, hence the components of the washing solution are not easily brought into the oil.

When the magnetic beads 7 pass through the interface between the second oil plug 46 and the reverse transcription reaction solution plug 47, the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. As a result, since the magnetic beads 7 pass through the interface without oscillating, the oil is not easily brought into the reverse transcription reaction solution plug 47.

When the magnetic beads 7 are present in the reverse transcription reaction solution plug 47, the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. As a result, since the reverse transcription reaction occurs in the state where the magnetic beads 7 do not oscillate, it is possible to inhibit the nucleic acid from being liberated from the magnetic beads 7 during the reverse transcription reaction.

When the magnetic beads 7 pass through the interface between the reverse transcription reaction solution 47 and oil (third oil plug 48), the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. As a result, since the magnetic beads 7 pass through the interface without oscillating, the components of the reverse transcription solution are not easily brought into the oil. Moreover, the controller 90 moves the magnets 71 in the vertical direction, in a state where one of the pair of magnets 71 is brought close to the tube 20. Therefore, the magnetic beads 7 close to the magnet 71 are attracted to the magnet and are aggregated, and the reverse transcription reaction solution having adhered to the magnetic beads 7 is squeezed out, hence the components of the reverse transcription reaction solution are not easily brought into the oil.

When the magnetic beads 7 pass through the interface between the third oil plug 48 and the eluate plug 49, the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. As a result, since the magnetic beads 7 pass through the interface without oscillating, the oil is not easily brought into the eluate plug 49.

When the magnetic beads 7 are in the eluate plug 49, the controller 90 drives the oscillation motor such that the magnets 71 oscillate in the front-back direction. In this manner, since the magnetic beads 7 oscillate in the front-back direction inside the eluate plug 49, the elution effect of the nucleic acid having bound to the magnetic beads 7 can be enhanced. Moreover, since the elution effect is enhanced, the time from when the magnetic beads 7 are introduced into the eluate 49 to when the elution of the nucleic acid is completed can be shortened.

When the nucleic acid is eluted in the eluate plug 49, and then the magnets 71 are moved upward to draw up the magnetic beads 7, the controller 90 stops the oscillation motor such that the magnets 71 do not oscillate. At this time, the controller 90 moves the magnets 71 downward, in a state where one of the pair of magnets 71 is brought close to the tube 20. As a result, the magnetic beads 7 easily follow the movement of the magnets 71, and the movement speed of the magnets 71 can be increased.

The memory of the controller 90 stores the information regarding the position of each plug of the capillary 23 and the information regarding oscillation as shown in FIG. 13. According to the information, the controller 90 executes the aforementioned operation (operation for causing the magnets 71 to oscillate).

(3) Solution Droplet Formation Process

FIGS. 14A to 14C are views for illustrating solution droplet formation process. FIG. 14A is a view for illustrating the state of the PCR device 100 at the time when the magnets 71 have been drawn up. FIG. 14B is a view for illustrating the state where the rotary body 61 has been rotated by 45°. FIG. 14C is a view for illustrating the state where the rod 82 of the pushing mechanism 80 has pushed the plunger 10.

As shown in FIG. 14A, when the carriage 73A is in the retraction position, the elevating mechanism 73 does not come into contact with the cartridge 1 even when the cartridge 1 rotates. After the PCR device 100 is put in this state, the controller 90 rotates the rotary body 61 by 45°.

As shown in FIG. 14B, when the rotary body 61 rotates by 45°, the longitudinal direction of the cartridge 1 is in parallel with the movement direction of the rod 82 of the pushing mechanism 80. The controller 90 drives the motor for a plunger 81 to move the rod 82. When the rod 82 comes into contact with the mounting board 11A of the plunger 10 of the cartridge 1 and then moves further, the plunger 10 is pushed into the tube 20. The controller 90 moves the rod 82 until the state shown in FIG. 14C is created and pushes the plunger 10 until the mounting board 11A of the plunger 10 comes into contact with the upper rim of the tube 20.

When the plunger 10 is pushed into the tube 20, the seal 12A of the rod-like portion 12 of the plunger 10 fits to the lower syringe 22 of the tube 20 (see FIG. 2B). Thereafter, when the plunger 10 is further pushed, the seal 12A slides inside the lower syringe 22. As a result, the liquid (the third oil plug 48, the eluate plug 49, and the like) of the downstream side of the tube 20 is pushed out to the flow path formation portion 35 of the PCR container 30, in such an amount corresponding to the volume in which the seal 12A slides inside the lower syringe 22.

First, the oil in the oil plugs (the fourth oil plug 50, the fifth oil plug 50B, and the like) in the lowermost portion of the downstream of the tube 20 flows into the flow path formation portion 35. Since the flow path formation portion 35 is filled with oil, the inflow oil flows into the oil accommodating space 32A from the flow path formation portion 35, whereby the oil interface of the oil accommodating space 32A ascends. At this time, due to pressure loss of the lower seal portion 34B, the pressure of the liquid in the flow path formation portion 35 becomes higher than the outside pressure (pressure of the oil accommodating space 32A). After the oil plugs in the lowermost position of the downstream are pushed out of the tube 20, the solution in the second plugs (the eluate plug 49, the nucleic acid amplification reaction solution plug 50A, and the like) from the lowermost position of the downstream flows into the flow path formation portion 35 from the tube 20. When the second plug from the lowermost portion of the downstream, such as the eluate plug 49, contains a nucleic acid to be amplified and the reagent for causing the nucleic acid amplification reaction, the inflow solution directly becomes the PCR solution 40 in the form of a droplet. When the cartridge 1 has the nucleic acid amplification reaction solution plug 50A and the like, and a nucleic acid to be amplified and the reagent for causing the nucleic acid amplification reaction are contained another plug, the plunger 10 is pushed until those two plugs flow into the flow path formation portion 35. Since the inner diameter of the flow path formation portion 35 is larger than the inner diameter of the capillary 23, those two plugs (for example, the eluate plug and the nucleic acid amplification reaction solution plug) having been in the form of a plug (column) inside the tube 20 are mixed with each other in the oil of the flow path formation portion 35, whereby the PCR solution 40 in the form of a droplet is formed. When the PCR container 30 has a droplet of the nucleic acid amplification reaction solution that undergoes phase separation when being mixed with oil and contains the reagent for causing the nucleic acid amplification reaction, the inflow eluate is mixed with the droplet of the nucleic acid amplification reaction solution in the oil of the flow path formation portion 35, whereby the PCR solution 40 is formed.

The volume in which the seal 12A slides inside the lower syringe 22 (the amount of the liquid in the tube 20 that is pushed out from the downstream side) is larger than the total volume of the eluate plug 49 and the third oil plug 48 in the tube 20. Therefore, after the eluate plug 49 is pushed out of the tube 20, a portion of the second oil plug 46 is also pushed out to the flow path formation portion 35. As a result, the eluate plug 49 does not remain in the tube 20, and the entire eluate plug 49 is formed into a droplet. Moreover, since a portion of the second oil plug 46 is pushed out of the downstream side of the tube 20, the PCR solution 40 in the form of a droplet easily leaves the tube 20 (the PCR solution 40 in the form of a droplet is not easily adsorbed onto the opening of the capillary 23).

The capillary 23 is designed such that the inner diameter of the terminal thereof (diameter of the opening of the capillary 23) is relatively small. Therefore, the PCR solution 40, which has been formed into a droplet in the PCR container 30, is not easily adsorbed onto the opening of the capillary 23. Moreover, the specific gravity of the PCR solution 40 is greater than that of the oil of the PCR container 30. Consequently, the PCR solution 40 in the form of a droplet leaves the terminal of the capillary 23, passes through the flow path formation portion 35 as a flow path, and is precipitated to the bottom 35A. Here, at this stage, since the flow path of the flow path formation portion 35 inclines by 45°, the PCR solution 40 in the form of a droplet easily adheres to the inner wall of the flow path formation portion 35. Therefore, the flow path of the flow path formation portion 35 needs to be returned to the vertical direction.

After the PCR solution 40 in the form of a droplet is formed (after the plunger 10 is pushed), the controller 90 drives the motor for a plunger 81 in a direction opposite to the direction in which the motor has been driven, such that the rod 82 returns to the original position. In this state, even if the cartridge 1 rotates, the rod 82 of the pushing mechanism 80 does not come into contact with the cartridge 1. After the PCR device is put in this state, the controller 90 returns the rotary body 61 to the standard position. When the rotary body 61 returns to the standard position, the flow path of the flow path formation portion 35 is in the vertical direction. Accordingly, the PCR solution 40 in the form of a droplet does not easily adhere to the inner wall of the flow path formation portion 35.

(4) Thermal Cycling Process

FIGS. 15A to 15D are views for illustrating thermal cycling process. FIG. 15B is a view for illustrating the state where the PCR solution 40 is subjected to temperature process at a low-temperature side. FIG. 15D is a view for illustrating the state where the PCR solution 40 is subjected to temperature process at a high-temperature side. The left side of each drawing describes the state of the PCR device 100, and the right side of each drawing describes the internal state of the flow path formation portion 35 of the PCR container 30.

When the cartridge 1 is fixed to a normal position in the mounting portion 62, the upstream side (high-temperature region 36A) of the flow path formation portion 35 of the PCR container 30 faces the high temperature-side heater 65B, and the downstream side (low-temperature region 36B) of the flow path formation portion 35 of the PCR container 30 faces the low temperature-side heater 65C. During the thermal cycling process, the controller 90 controls the high temperature-side heater 65B disposed in the rotary body 61, such that the liquid of the high-temperature region 36A of the upstream side of the flow path formation portion 35 of the PCR container 30 is heated to about 90° C. to 100° C. Moreover, the controller 90 controls the low temperature-side heater 65C disposed in the rotary body 61, such that the liquid of the low-temperature region 36B of the downstream side of the flow path formation portion 35 is heated to about 50° C. to 75° C. As a result, during the thermal cycling process, a temperature gradient is formed in the liquid in the flow path formation portion 35 of the PCR container 30. Since the mounting portion 62 and the heaters are disposed in the rotary body 61, the positional relationship between the cartridge 1 and the heaters is maintained in this state even when the rotary body 61 rotates.

During the thermal cycling process, the liquid in the PCR container 30 is heated. If air bubbles are formed in the liquid of the PCR container 30 due to heating of the liquid, the temperature of the liquid in the flow path formation portion 35 may become uneven, or movement (precipitation) of the PCR solution 40 in the form of a droplet that is caused in the flow path formation portion 35 may be hindered. However, in the present embodiment, due to the pressure loss caused in the lower seal portion 34B, the pressure of the liquid of the flow path formation portion 35 is higher than the outside pressure. Accordingly, air bubbles are not easily formed in the liquid of the PCR container 30.

As shown in FIG. 15A, when the rotary body 61 is in the standard position, the low temperature-side heater 65C is positioned below the high temperature-side heater 65B, and the bottom 35A of the PCR container 30 of the cartridge 1 becomes the lower side. Since the specific gravity of the PCR solution 40 in the form of a droplet is greater than that of oil, the PCR solution 40 in the form of a droplet is precipitated inside the flow path formation portion 35. After being precipitated inside the flow path formation portion 35, the PCR solution 40 in the form of a droplet reaches the bottom 35A of the PCR container 30. The precipitation of the reaction solution 47 is stopped at the bottom 35A, and the PCR solution stays in the low-temperature region 36B. In this manner, the PCR solution 40 in the form of a droplet moves to the low-temperature region 36B. The controller 90 maintains the state shown in FIG. 15B for a predetermined time and heats the PCR solution 40 in the form of a droplet to about 50° C. to 75° C. in the low-temperature region 36B (the PCR solution 40 is subjected to temperature process at the low-temperature side). Meanwhile, an extension reaction of the polymerase reaction occurs.

When the controller 90 drives the motor for rotation 66 in the state shown in FIG. 15A to rotate the rotary body 61 by 180°, the state shown in FIG. 15C is created. When the rotary body 61 rotates by 180° from the standard position, the cartridge 1 becomes upside down, and the high temperature-side heater 65B as well as the low temperature-side heater 65C also become upside down. That is, the high temperature-side heater 65B is positioned below the low temperature-side heater 65C, and the bottom 35A of the PCR container 30 of the cartridge 1 becomes the upper side. After being precipitated inside the flow path formation portion 35, the PCR solution 40 in the form of a droplet reaches the terminal of the tube 20 (terminal of the capillary 23). The precipitation of the reaction solution 47 is stopped at the terminal, and the PCR solution 40 stays in the high-temperature region 36A. In this manner, the PCR solution 40 in the form of a droplet moves to the high-temperature region 36A. The controller 90 maintains the state of FIG. 15D for a predetermined time, and heats the PCR solution 40 in the form of a droplet to about 90° C. to 100° C. in the high-temperature region 36A (the PCR solution 40 is subjected to temperature process at the high-temperature side). Meanwhile, a denaturation reaction of the polymerase reaction occurs.

When the controller 90 drives the motor for rotation 66 in the state of FIG. 15C to rotate the rotary body 61 by −180°, the PCR device returns to the state of FIG. 15A. When being precipitated inside the flow path formation portion 35 in this state, the PCR solution 40 in the form of a droplet moves to the low-temperature region 36B and is heated again to about 50° C. to 75° C. in the low-temperature region 36B (the PCR solution 40 is subjected to temperature process at the low-temperature side). Since the capillary 23 is designed such that the inner diameter of terminal thereof (diameter of the opening of the capillary 23) is relatively small, the PCR solution 40 is not easily adsorbed onto the opening of the capillary 23. Therefore, when the rotary body 61 rotates by −180° in the state of FIG. 15C, the PCR solution 40 in the form of a droplet leaves the tube 20 and is precipitated to the bottom 35A of the PCR container 30, without being adsorbed onto the opening of the capillary 23.

The controller 90 drives the motor for rotation 66 such that the rotation position of the rotary body 61 is put in the state of FIG. 15A and the state of FIG. 15C. The controller 90 repeats this operation for a predetermined cycle number. As a result, the PCR device 100 can perform the thermal cycling process of PCR on PCR solution 40.

The memory of the controller 90 stores the temperature of the high temperature-side heater 65B, the temperature of the low temperature-side heater 65C, the time during which the PCR device is held in the state of FIG. 15B, the time during which the PCR device is held in the state of FIG. 15D, and thermal cycling information of the cycle number (the number of times of repetition of the state of FIG. 15C and the state of FIG. 15D). According to the thermal cycling information, the controller 90 executes the above process.

(5) Fluorescence Measurement

As shown in FIG. 15A, when the rotary body 61 is in the standard position, the fluorescence measuring instrument 55 faces the bottom 35A of the PCR container 30 of the cartridge 1. Accordingly, at the time of performing fluorescence measurement on the PCR solution 40, the controller 90 controls the fluorescence measuring instrument 55 to measure fluorescence intensity of the PCR solution 40, which is in the bottom 35A of the PCR container 30, from the opening of the lower side of the insertion hole 64A of the low temperature-side heater 65C, in the state where the rotary body 61 is in the standard position.

Immediately after the rotary body 61 rotates by 180° and reaches the standard position, the PCR solution 40 in the form of a droplet is being precipitated in the flow path formation portion 35 of the PCR container 30 in some cases, hence the PCR solution 40 in the form of a droplet has not yet reached the bottom 35A of the PCR container 30. Therefore, it is desirable for the controller 90 to perform the fluorescence intensity after a predetermined time elapses from when the rotary body 61 is placed in the rotation position as shown in FIG. 15A (immediately before the rotary body 61 is rotated in the state of FIG. 15A). Alternatively, the controller 90 may control the fluorescence measuring instrument 55 to measure the fluorescence intensity during a predetermined period of time from when the rotary body 61 is placed in the standard position, and may store the time history of the fluorescence intensity.

EXAMPLES
(1) Constitution of Nucleic Acid Extraction Instrument

FIG. 16 shows a exploded view (FIG. 16A) describing the state where the nucleic acid extraction instrument used in the invention has not yet been assembled and a view (FIG. 16B) describing the state where the instrument has been completely assembled.

This instrument has a capillary 200 and a tank 120 which is for injecting liquid into the capillary 200. The capillary 200 and the tank 120 can constitute a kit for assembling the nucleic acid extraction instrument 130.

The capillary 200 has stoppers 110, and in the inside of the capillary, the first to seventh plugs are disposed. Each of these plugs is filled with an oil 710, a washing solution 720, an oil 730, a reverse transcription reaction solution 740, an oil 750, a washing solution 760, and an oil 770 in this order. The oil plays a role of separating the respective aqueous solutions from each other.

The tank 120 has an opening portion 121, a lid 122 that is attachable to and detachable from the opening portion 121, a space 123, and a lysing solution 124. Moreover, the lysing solution 124 contains magnetic beads 125 having silica-coated surface onto which the nucleic acid has been adsorbed.

When the stoppers 110 of the capillary 200 and the lid 122 of the tank 120 are removed, the capillary and the tank can be connected to each other as shown in FIG. 16B.

(2) Constitution of Nucleic Acid Extraction Device

A nucleic acid extraction device 3000 of the present example is a device on which a nucleic acid extraction instrument 2000 described in the section (1) is mounted to extract the nucleic acid (FIG. 17). The device 3000 has a mounting portion 300 on which the nucleic acid extraction instrument 2000 is mounted while being supported by a capillary 200, a magnetic force applying portion 400 that applies a magnetic force from the capillary 200 and optionally from the lateral side of the tank 120 when the nucleic acid extraction instrument 2000 has been mounted on the mounting portion 300, a movement mechanism 500 that changes the relative arrangement of the mounting portion 300 and the magnetic force applying portion 400 along the longitudinal direction of the capillary 200, and a heating portion 600 that heats a portion of the capillary 200. By changing the positional relationship between the mounting portion 300 and the magnetic force applying portion 400, the magnetic particles in the nucleic acid extraction instrument 2000 can be moved inside the instrument.

The mounting portion 300 has a splice plate 310 that is disposed such that the capillary 200 stands along the plate. By the splice plate 310, vibration or the like of the capillary 200 can be inhibited. The mounting portion 300 also has a clip mechanism 320, and by this mechanism, the capillary 200 is fixed to two sites.

The mounting portion 300 is constituted such that the positional relationship between the mounting portion 300 and the magnetic force applying portion 400 can be changed relative to the longitudinal direction of the capillary 200. In the present example, the nucleic acid extraction device is designed such that the mounting portion 300 can be moved relative to the magnetic force applying portion 400 without causing the magnetic force applying portion 400 to move. Accordingly, the movement mechanism 500 that moves the mounting portion 300 is disposed in the nucleic acid extraction device. Moreover, the mounting portion 300 includes a hinge 330, a guide rail 340, a driving belt 350, and a motor.

The magnetic force applying portion 400 has a pair of rectangular magnets 410 that faces each other while sandwiching the tank 120 and the capillary 200 therebetween. The pair of rectangular magnets 410 is in positions separated from each other by a distance larger than the outer diameter of the capillary 200. Moreover, the magnetic force applying portion 400 is disposed such that when one of the pair of rectangular magnets 410 approaches the capillary 200, the other magnet is separated from the capillary 200. Furthermore, by a motor 420, the pair of rectangular magnets 410 can oscillate so as to approach or be separated from the capillary 200 (the detail will be described later). The motor 420 can be driven as necessity even when a magnetic force is applied to the position of the tank 120 or the capillary 200.

The heating portion 600 can heat the fourth and sixth plugs of the capillary 200 when the capillary 200 has been mounted on the mounting portion 300. The heating portion 600 has two heaters that can be independently controlled.

In the nucleic acid extraction device 3000, even when the amount of the nucleic acid having been adsorbed onto magnetic particles M is reduced due to washing performed by at least one of the first washing solution of the second plug 720 and the second washing solution of the sixth plug 760, the nucleic acid can be eluted in a sufficient amount in the eluate of the fourth plug 740. As a result, it is possible to enhance the washing effect and to cause the nucleic acid to be eluted in the eluate at a concentration sufficient for PCR.

(3) How to Use Rectangular Magnets

FIG. 18 shows the capillary 200 and the rectangular magnets 410 among the constituents of the nucleic acid extraction device, and shows how to use the rectangular magnets 410.

The rectangular magnets 410 facing each other can easily sandwich the capillary 200 therebetween and can apply a magnetic force to the capillary 200 by simple operation such as vertical movement so as to cause the magnetic beads 125 in the capillary 200 to move up and down. As a result, an automated device can be obtained in a simple manner.

For example, as indicated by the symbol A, among the two rectangular magnets 410, which are at both sides of the capillary 200, the magnet at the left side is brought close to the capillary 200, the magnetic beads 125 are attracted to the left side of the capillary 200. Moreover, among the rectangular magnets 410, if the magnet at the right side is brought close to the capillary 200, the magnetic beads 125 are attracted to the right side of the capillary 200. Furthermore, as indicated by the symbol C, if both the rectangular magnets 410 are separated from the capillary 200, the magnetic beads 125 disperse in the capillary 200. Accordingly, by moving the rectangular magnets 410 to the left or right at the same place, the state indicated by the symbol A and the state indicated by the symbol B can be repeatedly created, whereby the magnetic beads 125 can be caused to oscillate.

(4) Nucleic Acid Extraction Method

Hereinafter, a nucleic acid extraction method using the nucleic acid extraction device 3000 (FIG. 17) having the capillary 200 will be described.

For diagnosing influenza, the lid 122 of a tank 120 is removed, and then a sample that has been collected from the mucous membrane of in the throat by using a cotton swab is inserted into the tank 120 containing the lysing solution 124 such that the cotton swab smeared with the collected sample is dipped into the lysing solution 124, whereby virus is collected into the lysing solution 124. The lysing solution 124 contains the magnetic beads 125 with a surface coated with silica. The tank 120 is shaken after the lid 122 is closed, whereby the nucleic acid is adsorbed onto the magnetic beads 125 (FIG. 16A).

Thereafter, the lid 122 of the tank 120 is removed again, the upper stopper 110 of the capillary 200 is removed, the tank 120 is connected to the capillary 200, and the capillary is disposed in a direction in parallel with the direction of gravity (FIG. 16B).

Subsequently, the rectangular magnets 410 are moved in the direction of gravity along the capillary 200, whereby the magnetic beads 125 pass through the inside of the respective plugs. During this process, the left and right rectangular magnets 410 may be used alternately such that the magnetic beads 125 oscillate to the left and right side (FIG. 18).

After being moved to the fourth plug, which has been heated to 45° C. in advance by using a heat block, the magnetic beads 125 are allowed to stop for 30 seconds to perform the reverse transcription reaction in a state where mRNA has been adsorbed onto the magnetic beads 125.

Thereafter, the magnetic beads 125 are moved again to the sixth plug, which has been heated to 80° C. in advance by using a heat block, and the rectangular magnets 410 are caused to oscillate for 30 seconds to cause elution of cDNA on the magnetic beads.

Finally, the lower stopper 110 of the capillary 200 is removed, and the tank 120 is squashed by being pushed from both sides thereof by fingers, such that the internal pressure of the tank 120 is increased, and the oil 770 and the eluate 760 are pushed out of the lower edge of the capillary 200. In this manner, the eluate 760 containing the eluted cDNA can be put into another container.

(5) Comparison Between 1-Step Elution and 2-Step Elution

By using a capillary having an inner diameter of 1.0 mm and a length of 100 mm and a tank having a volume of 10 mL, a nucleic acid extraction instrument (for 2-step elution) having the first to seventh plugs was prepared. The volume of the second plug was 25 μL, and the volume of the fourth and sixth plugs was 2 μL. Moreover, the length of each oil plug was 12.5 mm. For each plug, the following solution was used.

The second plug: 5 mM tris-hydrochloric acid buffer solution

The fourth plug:

0.2
u/μL
AMV reverse transcriptase (NIPPON GENE CO., LTD.)

0.8
mM
dNTP

0.5
μM
primer (reverse)

2.0
mg/mL
BSA

x1
buffer (7 mM MgCl₂;

25 mM Tris with pH 9.0; 50 mM KCl)

The sixth plug:

0.05
u/μL
Gene Taq NT PCR polymerase

(NIPPON GENE CO., LTD.)

0.5
mM
dNTP

0.5
μM
primer (forward)

0.5
μM
primer (reverse)

0.25
μM
probe (Taq man)

2.0
mg/mL
BSA

x1
buffer (7 mM MgCl₂;

25 mM Tris with pH 9.0; 50 mM KCl)

As a control, a capillary (for 1-step elution) which had the fourth plug, with which a reagent for PCR was mixed, without the sixth and seventh plugs and contained the following solution was used.

The fourth plug:

0.2
u/μL
AMV reverse transcriptase

(NIPPON GENE CO., LTD.)

0.125
u/μL
Gene Taq NT PCR polymerase

(NIPPON GENE CO., LTD.)

0.5
mM
dNTP

1.0
μM
primer (forward)

1.0
μM
primer (reverse)

0.5
μM
probe (Taq man)

4.0
mg/mL
BSA

x1
buffer (7 mM MgCl₂;

25 mM Tris with pH 9.0; 50 mM KCl)

Oligonucleotide sequence:

Primer (forward):

(SEQ ID NO: 1)

GAC CAA TCC TGT CAC CTC TGA C

Primer (reverse):

(SEQ ID NO: 2)

AGG GCA TTT TGG ACA AAG CGT CTA

Probe (Taq man):

(SEQ ID NO: 3)

FAM- TGC AGT CCT CGC TCA CTG GGC ACG -TAMRA

These capillaries were classified into three types including a capillary that was just prepared, a capillary that was stored for a week at 4° C., and a capillary that was stored for 6 months at 4° C. and used for the following experiment.

350 μL of a lysing solution [5 M guanidine thiocyanate, 2% Triton X-100, 50 mM Tris-HCl (pH 7.2)] and 2 μL of a magnetic beads dispersion were put into a tank, and a cotton swab used for collecting a sample was dipped into the tank. Then the tank was covered with a lid and shaken by about 100 times for 30 seconds to mix the content in the tank. As the magnetic beads dispersion, 30% by mass of an aqueous sodium chloride solution containing 30% by volume of magnetic silica particles (NPK-401, manufactured by TOYOBO CO., LTD.) was used.

The tank prepared as above was connected to the capillary, and the nucleic acid extraction instrument was disposed in a direction in parallel with the direction of gravity. Thereafter, the lateral surface of the container was brought into contact with magnets, steps of washing, reverse transcription, and elution were performed according to the method described above, and the eluate was discharged out of the capillary. All of the obtained eluate in an amount of 2 μL was used to perform a PCR reaction by using an elevating-type PCR device (device described in Example 1 of JP-A-2012-115208). FIGS. 19A and 19B show the change in luminance caused according to the increase in the PCR cycle number.

As shown in FIGS. 19A and 19B, in the 1-step elution performed using the control, for a week after the preparation of the capillary, the detection sensitivity had already been reduced, and after 6 months, the virus practically could not be detected. On the contrary, the 2-step elution performed using the invention, even after 6 months passed from when the capillary was prepared, reduction in the detection sensitivity practically was not observed.

When the invention was compared with the control by using the just prepared capillary (FIG. 20), the detection sensitivity was higher in the 2-step elution performed using the invention than in the 1-step elution performed using the control.

(6) In Case where the Number of Washing Plugs is Increased

Moreover, capillaries, which had a tenth plug formed of a washing solution that is not mixed with oil and an eleventh plug formed of oil in this order from the side of the fifth plug between the fifth and sixth plugs, were prepared. Immediately after being prepared, these capillaries were used for performing experiment. The tenth plug was the same plug as the second plug, and the eleventh plug was the same plug as other oil plugs. The experiment was performed under the same condition as in the section (5), except that these capillaries were used. FIG. 22 shows the change in luminance that is caused as the cycle number PCR increases.

The results obtained from this experiment were compared with the results obtained when the capillary did not have the tenth plug (washing plug) as in the section (5) (FIG. 21). The amplification efficiency of PCR became better when the number of the washing plugs was increased.

The entire disclosure of Japanese Patent Application No. 2013-050680, filed Mar. 13, 2013 is expressly incorporated by reference herein.

CARTRIDGE FOR NUCLEIC ACID AMPLIFICATION REACION

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)